{"id":2627,"date":"2026-03-10T21:53:48","date_gmt":"2026-03-10T21:53:48","guid":{"rendered":"https:\/\/psocan.marketaccess.ca\/traitements-traiter-le-pso-et-le-psa-vue-densemble\/liste-des-produits-biologiques-et-biosimilaires\/liste-des-produits-biologiques-et-biosimilaires-rhumatisme-psoriasique\/"},"modified":"2026-03-12T22:17:20","modified_gmt":"2026-03-12T22:17:20","slug":"liste-des-produits-biologiques-et-biosimilaires-rhumatisme-psoriasique","status":"publish","type":"page","link":"https:\/\/psoriasiscanada.ca\/fr\/traitements-traiter-le-pso-et-le-psa-vue-densemble\/liste-des-produits-biologiques-et-biosimilaires\/liste-des-produits-biologiques-et-biosimilaires-rhumatisme-psoriasique\/","title":{"rendered":"Liste des produits biologiques et biosimilaires (rhumatisme psoriasique)"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"2627\" class=\"elementor elementor-2627 elementor-2515\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-10557271 e-flex e-con-boxed e-con e-parent\" data-id=\"10557271\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a861396 elementor-widget elementor-widget-heading\" data-id=\"a861396\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Liste des produits biologiques et biosimilaires<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-dce7f0f elementor-widget elementor-widget-heading\" data-id=\"dce7f0f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Psoriasis<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-866a854 elementor-widget elementor-widget-heading\" data-id=\"866a854\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Bloqueurs du TNF<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8ecad31 elementor-widget elementor-widget-n-accordion\" data-id=\"8ecad31\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1490\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1490\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Etanercept (Enbrel\u00ae, biosimilaires : Erelzi\u2122, Brenzys\u00ae) <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1490\" class=\"elementor-element elementor-element-3f535a0 e-con-full e-flex e-con e-child\" data-id=\"3f535a0\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1490\" class=\"elementor-element elementor-element-8927128 e-flex e-con-boxed e-con e-child\" data-id=\"8927128\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8722857 e-n-tabs-mobile elementor-widget elementor-widget-n-tabs\" data-id=\"8722857\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;horizontal_scroll&quot;:&quot;disable&quot;}\" data-widget_type=\"nested-tabs.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-tabs\" data-widget-number=\"141699159\" aria-label=\"Onglets. Ouvrez des \u00e9l\u00e9ments avec Entrer ou Espace, fermez-les avec Echape et naviguez \u00e0 l&#039;aide des touches fl\u00e9ch\u00e9es.\">\n\t\t\t<div class=\"e-n-tabs-heading\" role=\"tablist\">\n\t\t\t\t\t<button id=\"e-n-tab-title-1416991591\" data-tab-title-id=\"e-n-tab-title-1416991591\" class=\"e-n-tab-title\" aria-selected=\"true\" data-tab-index=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"e-n-tab-content-1416991591\" style=\"--n-tabs-title-order: 1;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tD\u00e9tails\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-1416991592\" data-tab-title-id=\"e-n-tab-title-1416991592\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-1416991592\" style=\"--n-tabs-title-order: 2;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tTableaux du formulaire du programme public de m\u00e9dicaments\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t\t<\/div>\n\t\t\t<div class=\"e-n-tabs-content\">\n\t\t\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-1490 e-n-tab-title-1416991591\" id=\"e-n-tab-content-1416991591\" data-tab-index=\"1\" style=\"--n-tabs-title-order: 1;\" class=\"e-active elementor-element elementor-element-3fd7b54 e-con-full e-flex e-con e-child\" data-id=\"3fd7b54\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1490\" class=\"elementor-element elementor-element-6127ce4 e-flex e-con-boxed e-con e-child\" data-id=\"6127ce4\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-dbc389e elementor-widget elementor-widget-text-editor\" data-id=\"dbc389e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Comment cela fonctionne-t-il ?<\/h3><p>L&#8217;\u00e9tanercept est un m\u00e9dicament biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans le psoriasis. L&#8217;\u00e9tanercept agit en supprimant le facteur de n\u00e9crose tumorale alpha (TNFa).  Utile dans le psoriasis et l&#8217;arthrite psoriasique.<\/p><h3>Comment est-il utilis\u00e9 ?<\/h3><p>L&#8217;\u00e9tanercept est un m\u00e9dicament injectable administr\u00e9 par voie sous-cutan\u00e9e. Il peut \u00eatre dos\u00e9 \u00e0 domicile. <\/p><ul><li>Pour le psoriasis en plaques : 50 mg deux fois par semaine pendant 3 mois, puis 50 mg une fois par semaine.<\/li><li>Pour l&#8217;arthrite psoriasique : 50 mg une fois par semaine<\/li><\/ul><h3>Effets secondaires ?<\/h3><p>Les effets secondaires les plus fr\u00e9quents de l&#8217;\u00e9tanercept sont une douleur temporaire et une rougeur autour du site d&#8217;injection, ainsi qu&#8217;un risque accru d&#8217;infection. Pour obtenir une liste compl\u00e8te de tous les effets secondaires potentiels connus de l&#8217;\u00e9tanercept, parlez-en \u00e0 votre m\u00e9decin ou \u00e0 votre pharmacien. <\/p><h3>Consid\u00e9rations importantes ?<\/h3><p>Certaines vaccinations, connues sous le nom de vaccinations vivantes, doivent \u00eatre \u00e9vit\u00e9es pendant le traitement \u00e0 l&#8217;\u00e9tanercept. Avant de vous faire vacciner, demandez \u00e0 votre m\u00e9decin si le vaccin peut \u00eatre administr\u00e9 pendant le traitement \u00e0 l&#8217;\u00e9tanercept. <\/p><p>L&#8217;\u00e9tanercept et les autres m\u00e9dicaments inhibiteurs du TNF doivent \u00eatre \u00e9vit\u00e9s chez les patients atteints ou ayant un proche parent atteint de scl\u00e9rose en plaques. L&#8217;\u00e9tanercept doit \u00e9galement \u00eatre \u00e9vit\u00e9 chez les patients souffrant d&#8217;insuffisance cardiaque grave.  Les patients doivent faire l&#8217;objet d&#8217;un d\u00e9pistage de la tuberculose et de certaines infections fongiques invasives avant le traitement.<\/p><p>L&#8217;\u00e9tanercept doit \u00eatre \u00e9vit\u00e9 chez les patients immunod\u00e9prim\u00e9s ou s\u00e9ropositifs.<\/p><h3>Interactions ?<\/h3><p>Parmi les m\u00e9dicaments susceptibles d&#8217;interagir avec l&#8217;\u00e9tanercept figurent le denosumab, l&#8217;\u00e9chinac\u00e9e et le trastuzumab. Pour obtenir une liste compl\u00e8te des m\u00e9dicaments susceptibles d&#8217;interagir avec l&#8217;\u00e9tanercept et comprendre comment g\u00e9rer une interaction m\u00e9dicamenteuse potentielle, consultez votre m\u00e9decin ou votre pharmacien. <\/p><h3>Monographie du produit<\/h3><ul><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Brenzys\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Brenzys\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00065129.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00065129.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Brenzys\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Enbrel\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Brenzys\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Erelzi\u2122 <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00069556.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00069556.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Brenzys\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Rymti <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00068678.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00068678.PDF<\/a><\/span><\/li><\/ul><p>La monographie est cr\u00e9\u00e9e par Sant\u00e9 Canada pour r\u00e9sumer les preuves qu&#8217;il a examin\u00e9es afin d&#8217;autoriser la vente de ce m\u00e9dicament aux patients au Canada. Elle comprend des informations sur l&#8217;indication du m\u00e9dicament (raison pour laquelle il est utilis\u00e9), ses effets secondaires et toute information relative aux avertissements de s\u00e9curit\u00e9. Ces informations sont utilis\u00e9es par les prescripteurs, les pharmaciens, les assureurs et d&#8217;autres personnes pour utiliser le m\u00e9dicament en toute s\u00e9curit\u00e9. Les informations peuvent \u00eatre tr\u00e8s d\u00e9taill\u00e9es et nous vous encourageons \u00e0 poser toutes les questions que vous souhaitez \u00e0 votre m\u00e9decin.   <\/p><p><strong>Ce site est r\u00e9guli\u00e8rement mis \u00e0 jour, mais ces informations sont susceptibles d&#8217;\u00eatre modifi\u00e9es. Pour obtenir les informations les plus r\u00e9centes concernant les <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/www.canadianpsoriasisnetwork.com\/provincial-territorial-programs\/\">monographies<\/a><\/u> monographies de produits, <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/?lang=eng\">faites une recherche ici<\/a><\/u>. <\/strong><\/p><h3>Programme d&#8217;aide aux patients<\/h3><p>Etanercept (<sup>Enbrel\u00ae<\/sup>) <a href=\"https:\/\/www.amgen.ca\/products\/patient-assistance\/\" target=\"_blank\" rel=\"noopener noreferrer\">:<\/a> https:\/\/www.amgen.ca\/products\/patient-assistance\/<br>Biosimilaire de l&#8217;\u00e9tanercept (<sup>Erelzi\u2122<\/sup>) : Appelez le <strong>1-844-27XPOSE (1-844-279-7673) pour obtenir des informations.<\/strong><\/p><p>Brenzys<br>Programme de soutien aux patients Harmony<br>T\u00e9l\u00e9phone 1-866-556-5663<br><strong><a href=\"https:\/\/rheuminfo.com\/docs\/physician-tools\/patient-support-programs\/Brenzys_EN.pdf\">https:\/\/rheuminfo.com\/docs\/physician-tools\/patient-support-programs\/Brenzys_EN.pdf<\/a><\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-1490 e-n-tab-title-1416991592\" id=\"e-n-tab-content-1416991592\" data-tab-index=\"2\" style=\"--n-tabs-title-order: 2;\" class=\" elementor-element elementor-element-dffac4a e-con-full e-flex e-con e-child\" data-id=\"dffac4a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1490\" class=\"elementor-element elementor-element-60edf03 e-flex e-con-boxed e-con e-child\" data-id=\"60edf03\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7e72dd2 elementor-widget elementor-widget-shortcode\" data-id=\"7e72dd2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-shortcode\">\n<table id=\"tablepress-1\" class=\"tablepress tablepress-id-1\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Province<\/th><th class=\"column-2\">Class<\/th><th class=\"column-3\">Generic name<\/th><th class=\"column-4\">Drug Name<\/th><th class=\"column-5\">Psoriasis<\/th><th class=\"column-6\">Psoriatic arthritis<\/th><th class=\"column-7\">GPP<\/th><th class=\"column-8\">monograph<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Alberta<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">British Columbia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Manitoba<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">New Brunswick<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Newfoundland and Labrador<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">NIHB<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Northwest Territories<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Nova Scotia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Nunavut<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Ontario<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00065129.PDF<\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Prince Edward Island<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Quebec<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Saskatchewan<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Yukon<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Etanercept<\/td><td class=\"column-4\">Enbrel\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Enbrel (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00060454.PDF<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<!-- #tablepress-1 from cache -->\n<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1491\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"2\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1491\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Adalimumab (Humira\u00ae, biosimilaires : Hadlima\u00ae, Hyrimoz\u00ae, Idacio\u00ae, Amgevita\u00ae, Hulio\u00ae) <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1491\" class=\"elementor-element elementor-element-d0c9f85 e-con-full e-flex e-con e-child\" data-id=\"d0c9f85\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1491\" class=\"elementor-element elementor-element-fdc6d32 e-flex e-con-boxed e-con e-child\" data-id=\"fdc6d32\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-0d61ca4 e-n-tabs-mobile elementor-widget elementor-widget-n-tabs\" data-id=\"0d61ca4\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;horizontal_scroll&quot;:&quot;disable&quot;}\" data-widget_type=\"nested-tabs.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-tabs\" data-widget-number=\"14032036\" aria-label=\"Onglets. Ouvrez des \u00e9l\u00e9ments avec Entrer ou Espace, fermez-les avec Echape et naviguez \u00e0 l&#039;aide des touches fl\u00e9ch\u00e9es.\">\n\t\t\t<div class=\"e-n-tabs-heading\" role=\"tablist\">\n\t\t\t\t\t<button id=\"e-n-tab-title-140320361\" data-tab-title-id=\"e-n-tab-title-140320361\" class=\"e-n-tab-title\" aria-selected=\"true\" data-tab-index=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"e-n-tab-content-140320361\" style=\"--n-tabs-title-order: 1;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tD\u00e9tails\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-140320362\" data-tab-title-id=\"e-n-tab-title-140320362\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-140320362\" style=\"--n-tabs-title-order: 2;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tTableaux du formulaire du programme public de m\u00e9dicaments\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t\t<\/div>\n\t\t\t<div class=\"e-n-tabs-content\">\n\t\t\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-1491 e-n-tab-title-140320361\" id=\"e-n-tab-content-140320361\" data-tab-index=\"1\" style=\"--n-tabs-title-order: 1;\" class=\"e-active elementor-element elementor-element-18047fe e-con-full e-flex e-con e-child\" data-id=\"18047fe\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1491\" class=\"elementor-element elementor-element-4a07458 e-flex e-con-boxed e-con e-child\" data-id=\"4a07458\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d04c6ac elementor-widget elementor-widget-text-editor\" data-id=\"d04c6ac\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Comment cela fonctionne-t-il ?<\/h3><p>L&#8217;adalimumab est un produit biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans le psoriasis. L&#8217;adalimumab agit en inhibant le facteur de n\u00e9crose tumorale (TNFa). Il est utile pour le psoriasis et l&#8217;arthrite psoriasique.  <\/p><h3>Comment est-il utilis\u00e9 ?<\/h3><p>L&#8217;adalimumab est un m\u00e9dicament injectable administr\u00e9 par voie sous-cutan\u00e9e. Il peut \u00eatre administr\u00e9 \u00e0 domicile. <\/p><ul><li>Pour le psoriasis en plaques : 80 mg comme dose initiale, puis 40 mg toutes les deux semaines \u00e0 partir d&#8217;une semaine apr\u00e8s la dose initiale.<\/li><li>Pour l&#8217;arthrite psoriasique : 40 mg toutes les deux semaines<\/li><li>Pour le psoriasis en plaques : 50 mg deux fois par semaine pendant 3 mois, puis 50 mg une fois par semaine.<\/li><li>Pour l&#8217;arthrite psoriasique : 50 mg une fois par semaine<\/li><\/ul><h3>Effets secondaires ?<\/h3><p>Les effets secondaires les plus courants de l&#8217;adalimumab sont une douleur temporaire et une rougeur autour du point d&#8217;injection, des maux de t\u00eate et un risque accru d&#8217;infection. Pour obtenir une liste compl\u00e8te de tous les effets secondaires potentiels connus de l&#8217;adalimumab, consultez votre m\u00e9decin ou votre pharmacien. <\/p><h3>Consid\u00e9rations importantes ?<\/h3><p>Certains vaccins, appel\u00e9s vaccins vivants, doivent \u00eatre \u00e9vit\u00e9s pendant le traitement \u00e0 l&#8217;adalimumab. Avant de vous faire vacciner, demandez \u00e0 votre fournisseur de soins de sant\u00e9 si vous pouvez recevoir le vaccin pendant que vous prenez de l&#8217;adalimumab. <\/p><p>L&#8217;adalimumab et les autres m\u00e9dicaments inhibiteurs du TNF doivent \u00eatre \u00e9vit\u00e9s chez les patients atteints de scl\u00e9rose en plaques ou dont un proche parent est atteint de cette maladie. L&#8217;adalimumab doit \u00e9galement \u00eatre \u00e9vit\u00e9 chez les patients souffrant d&#8217;insuffisance cardiaque grave.  Les patients doivent faire l&#8217;objet d&#8217;un d\u00e9pistage de la tuberculose et de certaines infections fongiques invasives avant le traitement.<\/p><h3>Interactions ?<\/h3><p>Parmi les m\u00e9dicaments susceptibles d&#8217;interagir avec l&#8217;adalimumab figurent l&#8217;abatacept (Orencia\u00ae), l&#8217;anakinra (Kineret\u00ae) et d&#8217;autres bloqueurs du TNF comme Enbrel\u00ae, Remicade\u00ae, Cimzia\u00ae ou Simponi\u00ae. L&#8217;adalimumab peut potentiellement affecter la vitesse \u00e0 laquelle la cyclosporine et la warfarine sont m\u00e9tabolis\u00e9es et leurs doses pourraient devoir \u00eatre ajust\u00e9es. Pour obtenir une liste compl\u00e8te des m\u00e9dicaments susceptibles d&#8217;interagir avec l&#8217;adalimumab et pour comprendre comment g\u00e9rer une interaction m\u00e9dicamenteuse potentielle, consultez votre m\u00e9decin ou votre pharmacien.  <\/p><h3>Monographie du produit<\/h3><ul><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Hadlima\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Abrilada <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00068228.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00068228.PDF<\/a><\/span><\/li><li>Amgevita\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00067468.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00067468.PDF<\/a><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Hadlima\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Hadlima\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00068763.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00068763.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Hadlima\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Hulio\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00071858.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00071858.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Hadlima\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Humira\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Hadlima\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Hyrimoz\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00073497.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00073497.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Hadlima\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Idacio\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00058541.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00058541.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Hadlima\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Simlandi <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00075380.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00075380.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Hadlima\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Yuflyma <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00069429.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00069429.PDF<\/a><\/span><\/li><\/ul><p data-pm-slice=\"1 1 []\">La monographie est cr\u00e9\u00e9e par Sant\u00e9 Canada pour r\u00e9sumer les preuves qu&#8217;il a examin\u00e9es afin d&#8217;autoriser la vente de ce m\u00e9dicament aux patients au Canada. Elle comprend des informations sur l&#8217;indication du m\u00e9dicament (raison pour laquelle il est utilis\u00e9), ses effets secondaires et toute information relative aux avertissements de s\u00e9curit\u00e9. Ces informations sont utilis\u00e9es par les prescripteurs, les pharmaciens, les assureurs et d&#8217;autres personnes pour utiliser le m\u00e9dicament en toute s\u00e9curit\u00e9. Les informations peuvent \u00eatre tr\u00e8s d\u00e9taill\u00e9es et nous vous encourageons \u00e0 poser toutes les questions que vous souhaitez \u00e0 votre m\u00e9decin.    <\/p><p><strong>Ce site est r\u00e9guli\u00e8rement mis \u00e0 jour, mais ces informations sont susceptibles d&#8217;\u00eatre modifi\u00e9es. Pour obtenir les informations les plus r\u00e9centes concernant les <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/www.canadianpsoriasisnetwork.com\/provincial-territorial-programs\/\">monographies<\/a><\/u> monographies de produits, <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/?lang=eng\">faites une recherche ici<\/a><\/u>. <\/strong><\/p><h3>Programme d&#8217;aide aux patients<\/h3><p>Programme de soutien aux soins d&#8217;AbbVie<br><a href=\"https:\/\/abbviecare.ca\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/abbviecare.ca\/<\/a><\/p><p>Hadlima<br>T\u00e9l\u00e9phone 1-866-556-5663 | <a href=\"https:\/\/harmonyorganon.ca\/hadlima\/en\/index.html\" target=\"_blank\" rel=\"noopener\">https:\/\/harmonyorganon.ca\/hadlima\/en\/index.html<\/a><\/p><p>Hyrimoz<br>T\u00e9l\u00e9phone <a href=\"tel:18886726369\">1-888-6-SANDOZ (726369<\/a> ) | Courriel <a href=\"mailto:support.continum@sandoz.com\">support.continum@sandoz.com<\/a><\/p><p>Idacio<br>Programme d&#8217;aide aux patients d&#8217;Idacio KabiCare<br><a href=\"https:\/\/kabicare.ca\/\" target=\"_blank\" rel=\"noopener\">https:\/\/kabicare.ca<\/a> | T\u00e9l\u00e9phone 1-888-304-2034| Courriel <a href=\"mailto:info@kabicare.ca\">info@kabicare.ca<\/a><\/p><p>Amgevita<br>Enliven Services :<br>T\u00e9l\u00e9phone : 1-877-936-2735 | Courriel <a href=\"mailto:amgevita@oneenliven.ca\">amgevita@oneenliven.ca<\/a><br><a href=\"https:\/\/www.amgevita.ca\/\" target=\"_blank\" rel=\"noopener\">www.amgevita.ca<\/a><\/p><p>Hulio<br> hulio<a href=\"https:\/\/www.hulio.ca\/\" target=\"_blank\" rel=\"noopener\">.ca<\/a><br>T\u00e9l\u00e9phone : 1-844-485-4677 | Courriel <a href=\"mailto:hulio@assistprogram.com\">hulio@assistprogram.com<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-1491 e-n-tab-title-140320362\" id=\"e-n-tab-content-140320362\" data-tab-index=\"2\" style=\"--n-tabs-title-order: 2;\" class=\" elementor-element elementor-element-6d07db2 e-con-full e-flex e-con e-child\" data-id=\"6d07db2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1491\" class=\"elementor-element elementor-element-f709da8 e-flex e-con-boxed e-con e-child\" data-id=\"f709da8\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8a9b13f elementor-widget elementor-widget-shortcode\" data-id=\"8a9b13f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-shortcode\">\n<table id=\"tablepress-1-no-2\" class=\"tablepress tablepress-id-1\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Province<\/th><th class=\"column-2\">Class<\/th><th class=\"column-3\">Generic name<\/th><th class=\"column-4\">Drug Name<\/th><th class=\"column-5\">Psoriasis<\/th><th class=\"column-6\">Psoriatic arthritis<\/th><th class=\"column-7\">GPP<\/th><th class=\"column-8\">monograph<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Alberta<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">British Columbia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Manitoba<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">New Brunswick<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Newfoundland and Labrador<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">NIHB<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Northwest Territories<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Nova Scotia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Nunavut<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Ontario<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00068228.PDF<\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Prince Edward Island<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Quebec<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Saskatchewan<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Yukon<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Adalimumab<\/td><td class=\"column-4\">Humira\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Humira (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00067414.PDF<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<!-- #tablepress-1-no-2 from cache --><\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1492\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"3\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1492\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Infliximab (Remicade\u00ae, biosimilaires : Inflectra\u00ae, Renflexis\u00ae, Avsola\u00ae, Omvyence\u2122, Remsima\u2122). <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1492\" class=\"elementor-element elementor-element-1a13f15 e-con-full e-flex e-con e-child\" data-id=\"1a13f15\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1492\" class=\"elementor-element elementor-element-76c27bb e-flex e-con-boxed e-con e-child\" data-id=\"76c27bb\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ccbe152 e-n-tabs-mobile elementor-widget elementor-widget-n-tabs\" data-id=\"ccbe152\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;horizontal_scroll&quot;:&quot;disable&quot;}\" data-widget_type=\"nested-tabs.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-tabs\" data-widget-number=\"214688082\" aria-label=\"Onglets. Ouvrez des \u00e9l\u00e9ments avec Entrer ou Espace, fermez-les avec Echape et naviguez \u00e0 l&#039;aide des touches fl\u00e9ch\u00e9es.\">\n\t\t\t<div class=\"e-n-tabs-heading\" role=\"tablist\">\n\t\t\t\t\t<button id=\"e-n-tab-title-2146880821\" data-tab-title-id=\"e-n-tab-title-2146880821\" class=\"e-n-tab-title\" aria-selected=\"true\" data-tab-index=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"e-n-tab-content-2146880821\" style=\"--n-tabs-title-order: 1;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tD\u00e9tails\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-2146880822\" data-tab-title-id=\"e-n-tab-title-2146880822\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-2146880822\" style=\"--n-tabs-title-order: 2;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tTableaux du formulaire du programme public de m\u00e9dicaments\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t\t<\/div>\n\t\t\t<div class=\"e-n-tabs-content\">\n\t\t\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-1492 e-n-tab-title-2146880821\" id=\"e-n-tab-content-2146880821\" data-tab-index=\"1\" style=\"--n-tabs-title-order: 1;\" class=\"e-active elementor-element elementor-element-eb7fde2 e-con-full e-flex e-con e-child\" data-id=\"eb7fde2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1492\" class=\"elementor-element elementor-element-1d11ccd e-flex e-con-boxed e-con e-child\" data-id=\"1d11ccd\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5a72962 elementor-widget elementor-widget-text-editor\" data-id=\"5a72962\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Comment cela fonctionne-t-il ?<\/h3><p>L&#8217;infliximab est un m\u00e9dicament biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans le psoriasis. L&#8217;infliximab agit en supprimant le facteur de n\u00e9crose tumorale alpha (TNFa). Utile pour le psoriasis et l&#8217;arthrite psoriasique.  <\/p><h3>Comment est-il utilis\u00e9 ?<\/h3><p>L&#8217;infliximab est un m\u00e9dicament injectable administr\u00e9 par voie intraveineuse, utile dans le traitement du psoriasis et du rhumatisme psoriasique. Il est g\u00e9n\u00e9ralement administr\u00e9 dans un centre de perfusion. <\/p><ul><li>Pour le psoriasis en plaques : 5 mg\/kg \u00e0 0, 2 et 6 semaines, puis 5 mg\/kg toutes les 8 semaines.<\/li><li>Pour l&#8217;arthrite psoriasique : 5 mg\/kg \u00e0 0, 2 et 6 semaines, puis 5 mg\/kg toutes les 8 semaines.<\/li><\/ul><h3>Effets secondaires ?<\/h3><p>Les effets secondaires les plus fr\u00e9quents de l&#8217;infliximab sont une douleur temporaire et une rougeur autour du site de perfusion, des maux de t\u00eate, des naus\u00e9es, des douleurs articulaires et un risque accru d&#8217;infection. Pour obtenir une liste compl\u00e8te de tous les effets secondaires potentiels connus de l&#8217;infliximab, consultez votre m\u00e9decin ou votre pharmacien. <\/p><h3>Consid\u00e9rations importantes ?<\/h3><p>Certains vaccins, appel\u00e9s vaccins vivants, doivent \u00eatre \u00e9vit\u00e9s pendant le traitement par l&#8217;infliximab. Avant de vous faire vacciner, demandez \u00e0 votre m\u00e9decin si le vaccin peut \u00eatre administr\u00e9 pendant le traitement par l&#8217;infliximab. <\/p><p>L&#8217;infliximab et les autres m\u00e9dicaments inhibiteurs du TNF doivent \u00eatre \u00e9vit\u00e9s chez les patients atteints de scl\u00e9rose en plaques ou ayant un parent proche atteint de cette maladie. L&#8217;infliximab doit \u00e9galement \u00eatre \u00e9vit\u00e9 chez les patients souffrant d&#8217;insuffisance cardiaque grave.  Les patients doivent faire l&#8217;objet d&#8217;un d\u00e9pistage de la tuberculose et de certaines infections fongiques invasives avant le traitement.<\/p><h3>Interactions ?<\/h3><p>Certains m\u00e9dicaments peuvent interagir avec l&#8217;infliximab, notamment la ciclosporine, l&#8217;\u00e9chinac\u00e9e, la ph\u00e9nyto\u00efne et la warfarine. Pour obtenir une liste compl\u00e8te des m\u00e9dicaments susceptibles d&#8217;interagir avec l&#8217;infliximab et comprendre comment g\u00e9rer une interaction m\u00e9dicamenteuse potentielle, consultez votre m\u00e9decin ou votre pharmacien. <\/p><h3>Monographie du produit<\/h3><ul><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Avsola\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":2,\"2\":0},\"16\":10}\" data-sheets-textstyleruns=\"{\"1\":0}\uee10{\"1\":6,\"2\":{\"2\":{\"1\":3,\"3\":1},\"4\":10}}\">Avsola\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00065940.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00065940.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Avsola\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":2,\"2\":0},\"16\":10}\" data-sheets-textstyleruns=\"{\"1\":0}\uee10{\"1\":6,\"2\":{\"2\":{\"1\":3,\"3\":1},\"4\":10}}\">Inflectra\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00057004.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00057004.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Avsola\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":2,\"2\":0},\"16\":10}\" data-sheets-textstyleruns=\"{\"1\":0}\uee10{\"1\":6,\"2\":{\"2\":{\"1\":3,\"3\":1},\"4\":10}}\">Omvyence\u2122 <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00068865.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00068865.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Avsola\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":2,\"2\":0},\"16\":10}\" data-sheets-textstyleruns=\"{\"1\":0}\uee10{\"1\":6,\"2\":{\"2\":{\"1\":3,\"3\":1},\"4\":10}}\">Remicade\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Avsola\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":2,\"2\":0},\"16\":10}\" data-sheets-textstyleruns=\"{\"1\":0}\uee10{\"1\":6,\"2\":{\"2\":{\"1\":3,\"3\":1},\"4\":10}}\">Remsima\u2122 <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00074581.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00074581.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Avsola\u00ae\"}\" data-sheets-userformat=\"{\"2\":10689,\"3\":{\"1\":0,\"3\":1},\"9\":0,\"10\":0,\"11\":4,\"14\":{\"1\":2,\"2\":0},\"16\":10}\" data-sheets-textstyleruns=\"{\"1\":0}\uee10{\"1\":6,\"2\":{\"2\":{\"1\":3,\"3\":1},\"4\":10}}\">Renflexis\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00072737.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00072737.PDF<\/a><\/span><\/li><\/ul><p data-pm-slice=\"1 1 []\">La monographie est cr\u00e9\u00e9e par Sant\u00e9 Canada pour r\u00e9sumer les preuves qu&#8217;il a examin\u00e9es afin d&#8217;autoriser la vente de ce m\u00e9dicament aux patients au Canada. Elle comprend des informations sur l&#8217;indication du m\u00e9dicament (raison pour laquelle il est utilis\u00e9), ses effets secondaires et toute information relative aux avertissements de s\u00e9curit\u00e9. Ces informations sont utilis\u00e9es par les prescripteurs, les pharmaciens, les assureurs et d&#8217;autres personnes pour utiliser le m\u00e9dicament en toute s\u00e9curit\u00e9. Les informations peuvent \u00eatre tr\u00e8s d\u00e9taill\u00e9es et nous vous encourageons \u00e0 poser toutes les questions que vous souhaitez \u00e0 votre m\u00e9decin.   <\/p><p><strong>Ce site est r\u00e9guli\u00e8rement mis \u00e0 jour, mais ces informations sont susceptibles d&#8217;\u00eatre modifi\u00e9es. Pour obtenir les informations les plus r\u00e9centes concernant les <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/www.canadianpsoriasisnetwork.com\/provincial-territorial-programs\/\">monographies<\/a><\/u> monographies de produits, <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/?lang=eng\">faites une recherche ici<\/a><\/u>. <\/strong><\/p><h3>Programme d&#8217;aide aux patients<\/h3><p>Infliximab (<sup>Remicade\u00ae<\/sup>) <a href=\"https:\/\/www.bioadvancemember.ca\/en\/global\/home\" target=\"_blank\" rel=\"noopener noreferrer\">:<\/a> https:\/\/www.bioadvancemember.ca\/en\/global\/home<br><sup>Inflectra\u00ae<\/sup>, biosimilaire de l&#8217;infliximab <a href=\"https:\/\/www.pfizer.ca\/assistance-programs\" target=\"_blank\" rel=\"noopener noreferrer\">:<\/a> https:\/\/www.pfizer.ca\/assistance-programs<br><sup>Renflexis\u00ae<\/sup>, biosimilaire de l&#8217;infliximab <a href=\"http:\/\/www.merckharmony.ca\/\" target=\"_blank\" rel=\"noopener noreferrer\">: http:\/\/www.merckharmony.ca\/<\/a><\/p><p>Avsola<br>Enliven Services<br>Ph : 1-877-9ENBREL (936-2735) | Email <a href=\"mailto:info@oneenliven.ca\">info@oneenliven.ca<\/a><br><a href=\"https:\/\/www.enbrel.ca\/\" target=\"_blank\" rel=\"noopener\">www.enbrel.ca ;<\/a> <a href=\"https:\/\/www.avsola.ca\/\" target=\"_blank\" rel=\"noopener\">www.avsola.ca<\/a><\/p><p>Remsima<br>Programme de soutien aux patients CELLTRION CONNECT\u2122 pour Remsima<br>Les personnes int\u00e9ress\u00e9es peuvent en savoir plus sur CELLTRION CONNECT\u2122 en visitant le site <a href=\"http:\/\/www.celltrionconnect.ca\/\" target=\"_blank\" rel=\"noopener\">www.celltrionconnect.ca\/.<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-1492 e-n-tab-title-2146880822\" id=\"e-n-tab-content-2146880822\" data-tab-index=\"2\" style=\"--n-tabs-title-order: 2;\" class=\" elementor-element elementor-element-b4d8308 e-con-full e-flex e-con e-child\" data-id=\"b4d8308\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1492\" class=\"elementor-element elementor-element-0dfa466 e-flex e-con-boxed e-con e-child\" data-id=\"0dfa466\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-036f92d elementor-widget elementor-widget-shortcode\" data-id=\"036f92d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-shortcode\">\n<table id=\"tablepress-1-no-3\" class=\"tablepress tablepress-id-1\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Province<\/th><th class=\"column-2\">Class<\/th><th class=\"column-3\">Generic name<\/th><th class=\"column-4\">Drug Name<\/th><th class=\"column-5\">Psoriasis<\/th><th class=\"column-6\">Psoriatic arthritis<\/th><th class=\"column-7\">GPP<\/th><th class=\"column-8\">monograph<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Alberta<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">British Columbia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Manitoba<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">New Brunswick<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Newfoundland and Labrador<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">NIHB<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Northwest Territories<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Nova Scotia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Nunavut<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Ontario<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00065940.PDF<\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Prince Edward Island<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Quebec<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Saskatchewan<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Yukon<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Infliximab<\/td><td class=\"column-4\">Remicade\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075118.PDF<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<!-- #tablepress-1-no-3 from cache --><\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1493\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"4\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1493\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Golimumab (Simponi\u00ae) <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1493\" class=\"elementor-element elementor-element-4b953b4 e-con-full e-flex e-con e-child\" data-id=\"4b953b4\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1493\" class=\"elementor-element elementor-element-2fc756a e-flex e-con-boxed e-con e-child\" data-id=\"2fc756a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f6a3101 e-n-tabs-mobile elementor-widget elementor-widget-n-tabs\" data-id=\"f6a3101\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;horizontal_scroll&quot;:&quot;disable&quot;}\" data-widget_type=\"nested-tabs.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-tabs\" data-widget-number=\"258617601\" aria-label=\"Onglets. Ouvrez des \u00e9l\u00e9ments avec Entrer ou Espace, fermez-les avec Echape et naviguez \u00e0 l&#039;aide des touches fl\u00e9ch\u00e9es.\">\n\t\t\t<div class=\"e-n-tabs-heading\" role=\"tablist\">\n\t\t\t\t\t<button id=\"e-n-tab-title-2586176011\" data-tab-title-id=\"e-n-tab-title-2586176011\" class=\"e-n-tab-title\" aria-selected=\"true\" data-tab-index=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"e-n-tab-content-2586176011\" style=\"--n-tabs-title-order: 1;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tD\u00e9tails\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-2586176012\" data-tab-title-id=\"e-n-tab-title-2586176012\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-2586176012\" style=\"--n-tabs-title-order: 2;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tTableaux du formulaire du programme public de m\u00e9dicaments\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t\t<\/div>\n\t\t\t<div class=\"e-n-tabs-content\">\n\t\t\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-1493 e-n-tab-title-2586176011\" id=\"e-n-tab-content-2586176011\" data-tab-index=\"1\" style=\"--n-tabs-title-order: 1;\" class=\"e-active elementor-element elementor-element-443eaaf e-con-full e-flex e-con e-child\" data-id=\"443eaaf\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1493\" class=\"elementor-element elementor-element-14d2df9 e-flex e-con-boxed e-con e-child\" data-id=\"14d2df9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5417fb0 elementor-widget elementor-widget-text-editor\" data-id=\"5417fb0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Comment cela fonctionne-t-il ?<\/h3><p>Le golimumab est un m\u00e9dicament biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans l&#8217;<strong>arthrite psoriasique<\/strong>. Le golimumab agit en inhibant le facteur de n\u00e9crose tumorale alpha (TNFa). <\/p><h3>Comment est-il utilis\u00e9 ?<\/h3><p>Le golimumab est un m\u00e9dicament biologique qui peut \u00eatre administr\u00e9 par voie sous-cutan\u00e9e ou intraveineuse.<\/p><h3>Effets secondaires ?<\/h3><p>Les effets secondaires les plus fr\u00e9quents du golimumab sont un risque accru d&#8217;infection et une r\u00e9action temporaire au site d&#8217;injection. Pour obtenir une liste compl\u00e8te de tous les effets secondaires potentiels connus du golimumab, consultez votre m\u00e9decin ou votre pharmacien. <\/p><h3>Consid\u00e9rations importantes ?<\/h3><p>Certains vaccins, connus sous le nom de vaccins vivants, doivent \u00eatre \u00e9vit\u00e9s pendant le traitement au golimumab. Avant de recevoir un vaccin, demandez \u00e0 votre fournisseur de soins de sant\u00e9 si le vaccin peut \u00eatre administr\u00e9 pendant le traitement au golimumab. <\/p><p>Le golimumab doit \u00eatre \u00e9vit\u00e9 chez les patients souffrant d&#8217;insuffisance cardiaque grave.<\/p><p>Les patients doivent faire l&#8217;objet d&#8217;un d\u00e9pistage de la tuberculose et de certaines infections fongiques invasives avant le traitement.<\/p><h3>Interactions ?<\/h3><p>Parmi les m\u00e9dicaments susceptibles d&#8217;interagir avec le golimumab figurent l&#8217;abatacept, l&#8217;anakinra, le baricitinib, le belimumab, le canakizumab, le certolizumab pegol, la cladribine, l&#8217;\u00e9chinac\u00e9e, l&#8217;infliximab, le leflunomide, le natalizumab, le pim\u00e9crolimus, le rilonacept, le roflumilast, le tacrolimus, le tocilizumab, le tofacitinib, et le vedolizumab. Pour obtenir une liste compl\u00e8te des m\u00e9dicaments susceptibles d&#8217;interagir avec le golimumab et comprendre comment g\u00e9rer une interaction m\u00e9dicamenteuse potentielle, consultez votre m\u00e9decin ou votre pharmacien. <\/p><h3>Monographie du produit<\/h3><ul><li><a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/a><\/li><\/ul><p data-pm-slice=\"1 1 []\">La monographie est cr\u00e9\u00e9e par Sant\u00e9 Canada pour r\u00e9sumer les preuves qu&#8217;il a examin\u00e9es afin d&#8217;autoriser la vente de ce m\u00e9dicament aux patients au Canada. Elle comprend des informations sur l&#8217;indication du m\u00e9dicament (raison pour laquelle il est utilis\u00e9), ses effets secondaires et toute information relative aux avertissements de s\u00e9curit\u00e9. Ces informations sont utilis\u00e9es par les prescripteurs, les pharmaciens, les assureurs et d&#8217;autres personnes pour utiliser le m\u00e9dicament en toute s\u00e9curit\u00e9. Les informations peuvent \u00eatre tr\u00e8s d\u00e9taill\u00e9es et nous vous encourageons \u00e0 poser toutes les questions que vous souhaitez \u00e0 votre m\u00e9decin.   <\/p><p><strong>Ce site est r\u00e9guli\u00e8rement mis \u00e0 jour, mais ces informations sont susceptibles d&#8217;\u00eatre modifi\u00e9es. Pour obtenir les informations les plus r\u00e9centes concernant les <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/www.canadianpsoriasisnetwork.com\/provincial-territorial-programs\/\">monographies<\/a><\/u> monographies de produits, <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/?lang=eng\">faites une recherche ici<\/a><\/u>. <\/strong><\/p><h3>Programme d&#8217;aide aux patients<\/h3><p><a href=\"https:\/\/www.bioadvancemember.ca\/en\/global\/home\">https:\/\/www.bioadvancemember.ca\/en\/global\/home\n <\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-1493 e-n-tab-title-2586176012\" id=\"e-n-tab-content-2586176012\" data-tab-index=\"2\" style=\"--n-tabs-title-order: 2;\" class=\" elementor-element elementor-element-adf780e e-con-full e-flex e-con e-child\" data-id=\"adf780e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1493\" class=\"elementor-element elementor-element-54a99df e-flex e-con-boxed e-con e-child\" data-id=\"54a99df\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-aa79bc0 elementor-widget elementor-widget-shortcode\" data-id=\"aa79bc0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-shortcode\">\n<table id=\"tablepress-1-no-4\" class=\"tablepress tablepress-id-1\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Province<\/th><th class=\"column-2\">Class<\/th><th class=\"column-3\">Generic name<\/th><th class=\"column-4\">Drug Name<\/th><th class=\"column-5\">Psoriasis<\/th><th class=\"column-6\">Psoriatic arthritis<\/th><th class=\"column-7\">GPP<\/th><th class=\"column-8\">monograph<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Alberta<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">British Columbia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Manitoba<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">Yes \u2013 EDS<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">New Brunswick<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Newfoundland and Labrador<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">NIHB<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">Yes \u2013 L\/U<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Northwest Territories<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">Yes \u2013 L\/U<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Nova Scotia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Nunavut<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">Yes \u2013 L\/U<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Ontario<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">Yes - EAP<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Prince Edward Island<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">Yes \u2013 S\/A<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Quebec<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">Yes \u2013 S\/A<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Saskatchewan<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">Yes \u2013 EDS<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Yukon<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Golimumab<\/td><td class=\"column-4\">Simponi\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">Yes \u2013 EDS<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00074084.PDF<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1494\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"5\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1494\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Certolizumab pegol (Cimzia\u00ae) <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1494\" class=\"elementor-element elementor-element-4910e13 e-con-full e-flex e-con e-child\" data-id=\"4910e13\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1494\" class=\"elementor-element elementor-element-f60f31e e-flex e-con-boxed e-con e-child\" data-id=\"f60f31e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c00c57d e-n-tabs-mobile elementor-widget elementor-widget-n-tabs\" data-id=\"c00c57d\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;horizontal_scroll&quot;:&quot;disable&quot;}\" data-widget_type=\"nested-tabs.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-tabs\" data-widget-number=\"201377149\" aria-label=\"Onglets. Ouvrez des \u00e9l\u00e9ments avec Entrer ou Espace, fermez-les avec Echape et naviguez \u00e0 l&#039;aide des touches fl\u00e9ch\u00e9es.\">\n\t\t\t<div class=\"e-n-tabs-heading\" role=\"tablist\">\n\t\t\t\t\t<button id=\"e-n-tab-title-2013771491\" data-tab-title-id=\"e-n-tab-title-2013771491\" class=\"e-n-tab-title\" aria-selected=\"true\" data-tab-index=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"e-n-tab-content-2013771491\" style=\"--n-tabs-title-order: 1;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tD\u00e9tails\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-2013771492\" data-tab-title-id=\"e-n-tab-title-2013771492\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-2013771492\" style=\"--n-tabs-title-order: 2;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tTableaux du formulaire du programme public de m\u00e9dicaments\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t\t<\/div>\n\t\t\t<div class=\"e-n-tabs-content\">\n\t\t\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-1494 e-n-tab-title-2013771491\" id=\"e-n-tab-content-2013771491\" data-tab-index=\"1\" style=\"--n-tabs-title-order: 1;\" class=\"e-active elementor-element elementor-element-ccaf5b2 e-con-full e-flex e-con e-child\" data-id=\"ccaf5b2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1494\" class=\"elementor-element elementor-element-eadfad9 e-flex e-con-boxed e-con e-child\" data-id=\"eadfad9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-692a4da elementor-widget elementor-widget-text-editor\" data-id=\"692a4da\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Comment cela fonctionne-t-il ?<\/h3><p>Le certolizumab est un m\u00e9dicament biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans le psoriasis. Le certolizumab agit en inhibant le facteur de n\u00e9crose tumorale alpha (TNFa). <\/p><p>Utile dans le psoriasis et l&#8217;arthrite psoriasique.<\/p><h3>Comment est-il utilis\u00e9 ?<\/h3><p>Le certolizumab est un m\u00e9dicament injectable administr\u00e9 par voie sous-cutan\u00e9e.<\/p><ul><li>Pour le psoriasis en plaques : 400 mg toutes les 2 semaines<\/li><li>Pour l&#8217;arthrite psoriasique : 400 mg aux semaines 0, 2 et 4, suivis de 200 mg toutes les 2 semaines.<\/li><\/ul><h3>Effets secondaires ?<\/h3><p>Les effets secondaires les plus fr\u00e9quents du certolizumab sont des douleurs articulaires et un risque accru d&#8217;infections des voies respiratoires sup\u00e9rieures et d&#8217;infections urinaires. Pour obtenir une liste compl\u00e8te de tous les effets secondaires potentiels connus du certolizumab, parlez-en \u00e0 votre m\u00e9decin ou \u00e0 votre pharmacien. <\/p><h3>Consid\u00e9rations importantes ?<\/h3><p>Certaines vaccinations, connues sous le nom de vaccinations vivantes, doivent \u00eatre \u00e9vit\u00e9es pendant le traitement par certolizumab. Avant de recevoir un vaccin, demandez \u00e0 votre m\u00e9decin si le vaccin peut \u00eatre administr\u00e9 pendant le traitement par certolizumab. <\/p><p>Le certolizumab doit \u00eatre \u00e9vit\u00e9 chez les patients souffrant d&#8217;insuffisance cardiaque mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re.<\/p><p>Les patients doivent faire l&#8217;objet d&#8217;un d\u00e9pistage de la tuberculose et de certaines infections fongiques invasives avant le traitement.<\/p><h3>Interactions ?<\/h3><p>Parmi les m\u00e9dicaments susceptibles d&#8217;interagir avec le certolizumab figurent le denosumab, l&#8217;\u00e9chinac\u00e9e et le trastuzumab. Pour obtenir une liste compl\u00e8te des m\u00e9dicaments susceptibles d&#8217;interagir avec le certolizumab et comprendre comment g\u00e9rer une interaction m\u00e9dicamenteuse potentielle, consultez votre m\u00e9decin ou votre pharmacien. <\/p><h3>Monographie du produit<\/h3><ul><li><a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/a><\/li><\/ul><p data-pm-slice=\"1 1 []\">La monographie est cr\u00e9\u00e9e par Sant\u00e9 Canada pour r\u00e9sumer les preuves qu&#8217;il a examin\u00e9es afin d&#8217;autoriser la vente de ce m\u00e9dicament aux patients au Canada. Elle comprend des informations sur l&#8217;indication du m\u00e9dicament (raison pour laquelle il est utilis\u00e9), ses effets secondaires et toute information relative aux avertissements de s\u00e9curit\u00e9. Ces informations sont utilis\u00e9es par les prescripteurs, les pharmaciens, les assureurs et d&#8217;autres personnes pour utiliser le m\u00e9dicament en toute s\u00e9curit\u00e9. Les informations peuvent \u00eatre tr\u00e8s d\u00e9taill\u00e9es et nous vous encourageons \u00e0 poser toutes les questions que vous souhaitez \u00e0 votre m\u00e9decin.   <\/p><p><strong>Ce site est r\u00e9guli\u00e8rement mis \u00e0 jour, mais ces informations sont susceptibles d&#8217;\u00eatre modifi\u00e9es. Pour obtenir les informations les plus r\u00e9centes concernant les <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/www.canadianpsoriasisnetwork.com\/provincial-territorial-programs\/\">monographies<\/a><\/u> monographies de produits, <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/?lang=eng\">faites une recherche ici<\/a><\/u>. <\/strong><\/p><h3>Programme d&#8217;aide aux patients<\/h3><p>UCB Cares <a href=\"tel:18009085555\">1-800-908-5555<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-1494 e-n-tab-title-2013771492\" id=\"e-n-tab-content-2013771492\" data-tab-index=\"2\" style=\"--n-tabs-title-order: 2;\" class=\" elementor-element elementor-element-b7db5f8 e-con-full e-flex e-con e-child\" data-id=\"b7db5f8\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1494\" class=\"elementor-element elementor-element-f32b5d9 e-flex e-con-boxed e-con e-child\" data-id=\"f32b5d9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e63ec88 elementor-widget elementor-widget-shortcode\" data-id=\"e63ec88\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-shortcode\">\n<table id=\"tablepress-1-no-5\" class=\"tablepress tablepress-id-1\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Province<\/th><th class=\"column-2\">Class<\/th><th class=\"column-3\">Generic name<\/th><th class=\"column-4\">Drug Name<\/th><th class=\"column-5\">Psoriasis<\/th><th class=\"column-6\">Psoriatic arthritis<\/th><th class=\"column-7\">GPP<\/th><th class=\"column-8\">monograph<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Alberta<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">British Columbia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab-pergol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Manitoba<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">Yes \u2013 EDS<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">New Brunswick<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Newfoundland and Labrador<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">Yes \u2013 S\/A<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">NIHB<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">Yes \u2013 L\/U<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Northwest Territories<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">Yes \u2013 L\/U<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Nova Scotia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Nunavut<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">Yes \u2013 L\/U<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Ontario<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">Yes \u2013 EAP<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Prince Edward Island<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">Yes \u2013 S\/A<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Quebec<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">Yes \u2013 S\/A<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Saskatchewan<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\"><\/td><td class=\"column-6\"><\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Yukon<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Certolizumab pegol<\/td><td class=\"column-4\">Cimzia\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">Yes \u2013 EDS<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00053920.PDF<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5b0407d elementor-widget elementor-widget-heading\" data-id=\"5b0407d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Bloqueurs de l'IL17<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ec9d4f6 elementor-widget elementor-widget-n-accordion\" data-id=\"ec9d4f6\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2480\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2480\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Ixekizumab (Taltz\u00ae) <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2480\" class=\"elementor-element elementor-element-0dc98fb e-con-full e-flex e-con e-child\" data-id=\"0dc98fb\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2480\" class=\"elementor-element elementor-element-60f9277 e-flex e-con-boxed e-con e-child\" data-id=\"60f9277\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ea7a8ac e-n-tabs-mobile elementor-widget elementor-widget-n-tabs\" data-id=\"ea7a8ac\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;horizontal_scroll&quot;:&quot;disable&quot;}\" data-widget_type=\"nested-tabs.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-tabs\" data-widget-number=\"245868716\" aria-label=\"Onglets. Ouvrez des \u00e9l\u00e9ments avec Entrer ou Espace, fermez-les avec Echape et naviguez \u00e0 l&#039;aide des touches fl\u00e9ch\u00e9es.\">\n\t\t\t<div class=\"e-n-tabs-heading\" role=\"tablist\">\n\t\t\t\t\t<button id=\"e-n-tab-title-2458687161\" data-tab-title-id=\"e-n-tab-title-2458687161\" class=\"e-n-tab-title\" aria-selected=\"true\" data-tab-index=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"e-n-tab-content-2458687161\" style=\"--n-tabs-title-order: 1;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tD\u00e9tails\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-2458687162\" data-tab-title-id=\"e-n-tab-title-2458687162\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-2458687162\" style=\"--n-tabs-title-order: 2;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tTableaux du formulaire du programme public de m\u00e9dicaments\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t\t<\/div>\n\t\t\t<div class=\"e-n-tabs-content\">\n\t\t\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-2480 e-n-tab-title-2458687161\" id=\"e-n-tab-content-2458687161\" data-tab-index=\"1\" style=\"--n-tabs-title-order: 1;\" class=\"e-active elementor-element elementor-element-b675413 e-con-full e-flex e-con e-child\" data-id=\"b675413\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2480\" class=\"elementor-element elementor-element-fd89e65 e-flex e-con-boxed e-con e-child\" data-id=\"fd89e65\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-50c5101 elementor-widget elementor-widget-text-editor\" data-id=\"50c5101\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Comment cela fonctionne-t-il ?<\/h3><p>L&#8217;Ixekizumab est un m\u00e9dicament biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans le psoriasis. L&#8217;ixekizumab agit en supprimant l&#8217;interleukine-17A. Il est utile pour le psoriasis et l&#8217;arthrite psoriasique.  <\/p><h3>Comment est-il utilis\u00e9 ?<\/h3><p>L&#8217;ixekizumab est un m\u00e9dicament injectable administr\u00e9 par voie sous-cutan\u00e9e.<\/p><ul><li>Pour le psoriasis en plaques : 160 mg en une seule fois, suivis de 80 mg aux semaines 2, 4, 6, 8, 10 et 12, puis 80 mg toutes les 4 semaines.<\/li><li>Pour l&#8217;arthrite psoriasique : 160 mg en une seule fois, suivis de 80 mg toutes les 4 semaines.<\/li><\/ul><h3>Effets secondaires ?<\/h3><p>Les effets secondaires les plus fr\u00e9quents de l&#8217;ixekizumab sont une douleur temporaire et une rougeur autour du site d&#8217;injection, ainsi qu&#8217;un risque accru d&#8217;infection. Pour obtenir une liste compl\u00e8te de tous les effets secondaires potentiels connus de l&#8217;ixekizumab, parlez-en \u00e0 votre m\u00e9decin ou \u00e0 votre pharmacien. <\/p><h3>Consid\u00e9rations importantes ?<\/h3><p>Certaines vaccinations, connues sous le nom de vaccinations vivantes, doivent \u00eatre \u00e9vit\u00e9es pendant le traitement par l&#8217;ixekizumab. Avant de vous faire vacciner, demandez \u00e0 votre m\u00e9decin si le vaccin peut \u00eatre administr\u00e9 pendant le traitement par l&#8217;ixekizumab. <\/p><p>L&#8217;ixekizumab doit \u00eatre \u00e9vit\u00e9 chez les patients pr\u00e9sentant une maladie inflammatoire de l&#8217;intestin en cours d&#8217;\u00e9volution ou ayant des ant\u00e9c\u00e9dents de maladie inflammatoire de l&#8217;intestin.<\/p><p>Les patients doivent faire l&#8217;objet d&#8217;un d\u00e9pistage de la tuberculose et de certaines infections fongiques invasives avant le traitement.<\/p><h3>Interactions ?<\/h3><p>Parmi les m\u00e9dicaments susceptibles d&#8217;interagir avec l&#8217;ixekizumab figurent le denosumab, l&#8217;\u00e9chinac\u00e9e et le trastuzumab. Pour obtenir une liste compl\u00e8te des m\u00e9dicaments susceptibles d&#8217;interagir avec l&#8217;ixekizumab et comprendre comment g\u00e9rer une interaction m\u00e9dicamenteuse potentielle, consultez votre m\u00e9decin ou votre pharmacien. <\/p><h3>Monographie du produit<\/h3><ul><li><a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/a><\/li><\/ul><p data-pm-slice=\"1 1 []\">La monographie est cr\u00e9\u00e9e par Sant\u00e9 Canada pour r\u00e9sumer les preuves qu&#8217;il a examin\u00e9es afin d&#8217;autoriser la vente de ce m\u00e9dicament aux patients au Canada. Elle comprend des informations sur l&#8217;indication du m\u00e9dicament (raison pour laquelle il est utilis\u00e9), ses effets secondaires et toute information relative aux avertissements de s\u00e9curit\u00e9. Ces informations sont utilis\u00e9es par les prescripteurs, les pharmaciens, les assureurs et d&#8217;autres personnes pour utiliser le m\u00e9dicament en toute s\u00e9curit\u00e9. Les informations peuvent \u00eatre tr\u00e8s d\u00e9taill\u00e9es et nous vous encourageons \u00e0 poser toutes les questions que vous souhaitez \u00e0 votre m\u00e9decin.   <\/p><p><strong>Ce site est r\u00e9guli\u00e8rement mis \u00e0 jour, mais ces informations sont susceptibles d&#8217;\u00eatre modifi\u00e9es. Pour obtenir les informations les plus r\u00e9centes concernant les <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/www.canadianpsoriasisnetwork.com\/provincial-territorial-programs\/\">monographies<\/a><\/u> monographies de produits, <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/?lang=eng\">faites une recherche ici<\/a><\/u>. <\/strong><\/p><h3>Programme d&#8217;aide aux patients<\/h3><p>Appelez le 1-877-219-8908 pour obtenir des informations.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-2480 e-n-tab-title-2458687162\" id=\"e-n-tab-content-2458687162\" data-tab-index=\"2\" style=\"--n-tabs-title-order: 2;\" class=\" elementor-element elementor-element-4fc68a4 e-con-full e-flex e-con e-child\" data-id=\"4fc68a4\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2480\" class=\"elementor-element elementor-element-5091929 e-flex e-con-boxed e-con e-child\" data-id=\"5091929\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-09cfca2 elementor-widget elementor-widget-shortcode\" data-id=\"09cfca2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-shortcode\">\n<table id=\"tablepress-1-no-6\" class=\"tablepress tablepress-id-1\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Province<\/th><th class=\"column-2\">Class<\/th><th class=\"column-3\">Generic name<\/th><th class=\"column-4\">Drug Name<\/th><th class=\"column-5\">Psoriasis<\/th><th class=\"column-6\">Psoriatic arthritis<\/th><th class=\"column-7\">GPP<\/th><th class=\"column-8\">monograph<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Alberta<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">British Columbia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Manitoba<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">New Brunswick<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Newfoundland and Labrador<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">NIHB<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Northwest Territories<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Nova Scotia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Nunavut<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Ontario<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Prince Edward Island<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Quebec<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Saskatchewan<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Yukon<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ixekizumab<\/td><td class=\"column-4\">Taltz\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00069828.PDF<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2481\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"2\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2481\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Secukinumab (Cosentyx\u00ae) <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2481\" class=\"elementor-element elementor-element-9f8592d e-con-full e-flex e-con e-child\" data-id=\"9f8592d\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2481\" class=\"elementor-element elementor-element-6738947 e-flex e-con-boxed e-con e-child\" data-id=\"6738947\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1f7472a e-n-tabs-mobile elementor-widget elementor-widget-n-tabs\" data-id=\"1f7472a\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;horizontal_scroll&quot;:&quot;disable&quot;}\" data-widget_type=\"nested-tabs.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-tabs\" data-widget-number=\"32982826\" aria-label=\"Onglets. Ouvrez des \u00e9l\u00e9ments avec Entrer ou Espace, fermez-les avec Echape et naviguez \u00e0 l&#039;aide des touches fl\u00e9ch\u00e9es.\">\n\t\t\t<div class=\"e-n-tabs-heading\" role=\"tablist\">\n\t\t\t\t\t<button id=\"e-n-tab-title-329828261\" data-tab-title-id=\"e-n-tab-title-329828261\" class=\"e-n-tab-title\" aria-selected=\"true\" data-tab-index=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"e-n-tab-content-329828261\" style=\"--n-tabs-title-order: 1;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tD\u00e9tails\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-329828262\" data-tab-title-id=\"e-n-tab-title-329828262\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-329828262\" style=\"--n-tabs-title-order: 2;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tTableaux du formulaire du programme public de m\u00e9dicaments\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t\t<\/div>\n\t\t\t<div class=\"e-n-tabs-content\">\n\t\t\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-2481 e-n-tab-title-329828261\" id=\"e-n-tab-content-329828261\" data-tab-index=\"1\" style=\"--n-tabs-title-order: 1;\" class=\"e-active elementor-element elementor-element-9082cd4 e-con-full e-flex e-con e-child\" data-id=\"9082cd4\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2481\" class=\"elementor-element elementor-element-e959e2c e-flex e-con-boxed e-con e-child\" data-id=\"e959e2c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c7b3b69 elementor-widget elementor-widget-text-editor\" data-id=\"c7b3b69\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Comment cela fonctionne-t-il ?<\/h3><p>Le s\u00e9cukinumab est un m\u00e9dicament biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans le psoriasis. Le s\u00e9cukinumab agit en supprimant l&#8217;interleukine-17A. Il est utile pour le psoriasis et l&#8217;arthrite psoriasique.  <\/p><h3>Comment est-il utilis\u00e9 ?<\/h3><p>Le s\u00e9cukinumab est un m\u00e9dicament injectable administr\u00e9 par voie sous-cutan\u00e9e.<\/p><ul><li>Pour le psoriasis en plaques : 300 mg une fois par semaine aux semaines 0, 1, 2, 3 et 4, puis 300 mg toutes les 4 semaines.<\/li><li>Pour le rhumatisme psoriasique : Pour les patients qui n&#8217;ont pas \u00e9t\u00e9 trait\u00e9s auparavant par un agent biologique &#8211; 150 mg (ou 300 mg pour certains patients) une fois par semaine aux semaines 0, 1, 2, 3 et 4, suivis de 150 mg toutes les 4 semaines. Pour les patients ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s par un agent biologique &#8211; 300 mg une fois par semaine aux semaines 0, 1, 2, 3 et 4, suivis de 300 mg toutes les 4 semaines. <\/li><\/ul><h3>Effets secondaires ?<\/h3><p>L&#8217;effet secondaire le plus fr\u00e9quent du s\u00e9cukinumab est une augmentation du risque d&#8217;infection. Pour obtenir une liste compl\u00e8te de tous les effets secondaires potentiels connus du s\u00e9cukinumab, parlez-en \u00e0 votre m\u00e9decin ou \u00e0 votre pharmacien. <\/p><h3>Consid\u00e9rations importantes ?<\/h3><p>Certaines vaccinations, connues sous le nom de vaccinations vivantes, doivent \u00eatre \u00e9vit\u00e9es pendant le traitement par le s\u00e9cukinumab. Avant de recevoir un vaccin, demandez \u00e0 votre m\u00e9decin si le vaccin peut \u00eatre administr\u00e9 pendant le traitement par le s\u00e9cukinumab. <\/p><p>Le s\u00e9cukinumab doit \u00eatre \u00e9vit\u00e9 chez les patients souffrant d&#8217;une maladie inflammatoire de l&#8217;intestin en cours d&#8217;\u00e9volution ou ayant des ant\u00e9c\u00e9dents de maladie inflammatoire de l&#8217;intestin.<\/p><p>Les patients doivent faire l&#8217;objet d&#8217;un d\u00e9pistage de la tuberculose et de certaines infections fongiques invasives avant le traitement.<\/p><h3>Interactions ?<\/h3><p>Parmi les m\u00e9dicaments susceptibles d&#8217;interagir avec le s\u00e9cukinumab figurent le denosumab, l&#8217;\u00e9chinac\u00e9e et le trastuzumab. Pour obtenir une liste compl\u00e8te des m\u00e9dicaments susceptibles d&#8217;interagir avec le s\u00e9cukinumab et comprendre comment g\u00e9rer une interaction m\u00e9dicamenteuse potentielle, consultez votre m\u00e9decin ou votre pharmacien. <\/p><h3>Monographie du produit<\/h3><ul><li><a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/a><\/li><\/ul><p data-pm-slice=\"1 1 []\">La monographie est cr\u00e9\u00e9e par Sant\u00e9 Canada pour r\u00e9sumer les preuves qu&#8217;il a examin\u00e9es afin d&#8217;autoriser la vente de ce m\u00e9dicament aux patients au Canada. Elle comprend des informations sur l&#8217;indication du m\u00e9dicament (raison pour laquelle il est utilis\u00e9), ses effets secondaires et toute information relative aux avertissements de s\u00e9curit\u00e9. Ces informations sont utilis\u00e9es par les prescripteurs, les pharmaciens, les assureurs et d&#8217;autres personnes pour utiliser le m\u00e9dicament en toute s\u00e9curit\u00e9. Les informations peuvent \u00eatre tr\u00e8s d\u00e9taill\u00e9es et nous vous encourageons \u00e0 poser toutes les questions que vous souhaitez \u00e0 votre m\u00e9decin.   <\/p><p><strong>Ce site est r\u00e9guli\u00e8rement mis \u00e0 jour, mais ces informations sont susceptibles d&#8217;\u00eatre modifi\u00e9es. Pour obtenir les informations les plus r\u00e9centes concernant les <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/www.canadianpsoriasisnetwork.com\/provincial-territorial-programs\/\">monographies<\/a><\/u> monographies de produits, <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/?lang=eng\">faites une recherche ici<\/a><\/u>. <\/strong><\/p><h3>Programme d&#8217;aide aux patients<\/h3><p><a href=\"https:\/\/www.cosentyx.ca\/home\/plaque-psoriasis\/xpose-your-support-network\/\">https:\/\/www.cosentyx.ca\/home\/plaque-psoriasis\/xpose-your-support-network\/<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-2481 e-n-tab-title-329828262\" id=\"e-n-tab-content-329828262\" data-tab-index=\"2\" style=\"--n-tabs-title-order: 2;\" class=\" elementor-element elementor-element-5a89802 e-con-full e-flex e-con e-child\" data-id=\"5a89802\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2481\" class=\"elementor-element elementor-element-4471af5 e-flex e-con-boxed e-con e-child\" data-id=\"4471af5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-cafc723 elementor-widget elementor-widget-shortcode\" data-id=\"cafc723\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-shortcode\">\n<table id=\"tablepress-1-no-7\" class=\"tablepress tablepress-id-1\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Province<\/th><th class=\"column-2\">Class<\/th><th class=\"column-3\">Generic name<\/th><th class=\"column-4\">Drug Name<\/th><th class=\"column-5\">Psoriasis<\/th><th class=\"column-6\">Psoriatic arthritis<\/th><th class=\"column-7\">GPP<\/th><th class=\"column-8\">monograph<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Alberta<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">British Columbia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Manitoba<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">New Brunswick<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Newfoundland and Labrador<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">NIHB<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Northwest Territories<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Nova Scotia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Nunavut<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Ontario<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Prince Edward Island<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Quebec<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Saskatchewan<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Yukon<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Secukinumab<\/td><td class=\"column-4\">Cosentyx\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075631.PDF<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<!-- #tablepress-1-no-7 from cache --><\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-eafaae9 elementor-widget elementor-widget-heading\" data-id=\"eafaae9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Bloqueurs de l'IL12\/23<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-302220a elementor-widget elementor-widget-n-accordion\" data-id=\"302220a\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-5040\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-5040\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Ustekinumab (Stelara\u00ae) <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5040\" class=\"elementor-element elementor-element-f59d094 e-con-full e-flex e-con e-child\" data-id=\"f59d094\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5040\" class=\"elementor-element elementor-element-9caa3a3 e-flex e-con-boxed e-con e-child\" data-id=\"9caa3a3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5a21eca e-n-tabs-mobile elementor-widget elementor-widget-n-tabs\" data-id=\"5a21eca\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;horizontal_scroll&quot;:&quot;disable&quot;}\" data-widget_type=\"nested-tabs.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-tabs\" data-widget-number=\"94510794\" aria-label=\"Onglets. Ouvrez des \u00e9l\u00e9ments avec Entrer ou Espace, fermez-les avec Echape et naviguez \u00e0 l&#039;aide des touches fl\u00e9ch\u00e9es.\">\n\t\t\t<div class=\"e-n-tabs-heading\" role=\"tablist\">\n\t\t\t\t\t<button id=\"e-n-tab-title-945107941\" data-tab-title-id=\"e-n-tab-title-945107941\" class=\"e-n-tab-title\" aria-selected=\"true\" data-tab-index=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"e-n-tab-content-945107941\" style=\"--n-tabs-title-order: 1;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tD\u00e9tails\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-945107942\" data-tab-title-id=\"e-n-tab-title-945107942\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-945107942\" style=\"--n-tabs-title-order: 2;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tTableaux du formulaire du programme public de m\u00e9dicaments\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t\t<\/div>\n\t\t\t<div class=\"e-n-tabs-content\">\n\t\t\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-5040 e-n-tab-title-945107941\" id=\"e-n-tab-content-945107941\" data-tab-index=\"1\" style=\"--n-tabs-title-order: 1;\" class=\"e-active elementor-element elementor-element-0ddc4ee e-con-full e-flex e-con e-child\" data-id=\"0ddc4ee\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5040\" class=\"elementor-element elementor-element-4516c52 e-flex e-con-boxed e-con e-child\" data-id=\"4516c52\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6dea98a elementor-widget elementor-widget-text-editor\" data-id=\"6dea98a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Comment cela fonctionne-t-il ?<\/h3><p>L&#8217;ustekinumab est un m\u00e9dicament biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans le psoriasis. L&#8217;ustekinumab agit en supprimant l&#8217;interleukine 12 et l&#8217;interleukine 23. Il est utile pour le psoriasis et l&#8217;arthrite psoriasique.  <\/p><h3>Comment est-il utilis\u00e9 ?<\/h3><p>L&#8217;ustekinumab est un m\u00e9dicament injectable administr\u00e9 par voie sous-cutan\u00e9e. Il peut \u00eatre administr\u00e9 \u00e0 domicile. <\/p><ul><li>Pour le psoriasis en plaques : <br>\u2264100 kg : 45 mg \u00e0 0 et 4 semaines, puis toutes les 12 semaines<br>&gt;100 kg : 90 mg \u00e0 0 et 4 semaines, puis toutes les 12 semaines.<\/li><li>Pour le rhumatisme psoriasique : 45 mg \u00e0 0 et 4 semaines, puis toutes les 12 semaines.<\/li><\/ul><h3>Effets secondaires ?<\/h3><p>L&#8217;effet secondaire le plus fr\u00e9quent de l&#8217;ustekinumab est un risque accru d&#8217;infection. Pour obtenir une liste compl\u00e8te de tous les effets secondaires potentiels connus de l&#8217;ustekinumab, parlez-en \u00e0 votre m\u00e9decin ou \u00e0 votre pharmacien. <\/p><h3>Consid\u00e9rations importantes ?<\/h3><p>Certaines vaccinations, connues sous le nom de vaccinations vivantes, doivent \u00eatre \u00e9vit\u00e9es pendant le traitement par l&#8217;ustekinumab. Avant de vous faire vacciner, demandez \u00e0 votre m\u00e9decin si vous pouvez recevoir le vaccin pendant votre traitement par l&#8217;ustekinumab. <\/p><p>Les patients doivent faire l&#8217;objet d&#8217;un d\u00e9pistage de la tuberculose et de certaines infections fongiques invasives avant le traitement.<\/p><h3>Interactions ?<\/h3><p>Parmi les m\u00e9dicaments susceptibles d&#8217;interagir avec l&#8217;ustekinumab figurent le denosumab, l&#8217;\u00e9chinac\u00e9e et le trastuzumab. Pour obtenir une liste compl\u00e8te des m\u00e9dicaments susceptibles d&#8217;interagir avec l&#8217;ustekinumab et comprendre comment g\u00e9rer une interaction m\u00e9dicamenteuse potentielle, consultez votre m\u00e9decin ou votre pharmacien. <\/p><h3>Monographie du produit<\/h3><ul><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Jamteki\"}\" data-sheets-userformat=\"{\"2\":11201,\"3\":{\"1\":0},\"9\":0,\"10\":0,\"11\":4,\"12\":0,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Jamteki <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00073286.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00073286.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Jamteki\"}\" data-sheets-userformat=\"{\"2\":11201,\"3\":{\"1\":0},\"9\":0,\"10\":0,\"11\":4,\"12\":0,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Stelara\u00ae <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/a><\/span><\/li><li><span data-sheets-root=\"1\" data-sheets-value=\"{\"1\":2,\"2\":\"Jamteki\"}\" data-sheets-userformat=\"{\"2\":11201,\"3\":{\"1\":0},\"9\":0,\"10\":0,\"11\":4,\"12\":0,\"14\":{\"1\":3,\"3\":1},\"16\":10}\">Wezlana <a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00073953.PDF\">: https:\/\/pdf.hres.ca\/dpd_pm\/00073953.PDF<\/a><\/span><\/li><\/ul><p data-pm-slice=\"1 1 []\">La monographie est cr\u00e9\u00e9e par Sant\u00e9 Canada pour r\u00e9sumer les preuves qu&#8217;il a examin\u00e9es afin d&#8217;autoriser la vente de ce m\u00e9dicament aux patients au Canada. Elle comprend des informations sur l&#8217;indication du m\u00e9dicament (raison pour laquelle il est utilis\u00e9), ses effets secondaires et toute information relative aux avertissements de s\u00e9curit\u00e9. Ces informations sont utilis\u00e9es par les prescripteurs, les pharmaciens, les assureurs et d&#8217;autres personnes pour utiliser le m\u00e9dicament en toute s\u00e9curit\u00e9. Les informations peuvent \u00eatre tr\u00e8s d\u00e9taill\u00e9es et nous vous encourageons \u00e0 poser toutes les questions que vous souhaitez \u00e0 votre m\u00e9decin.   <\/p><p><strong>Ce site est r\u00e9guli\u00e8rement mis \u00e0 jour, mais ces informations sont susceptibles d&#8217;\u00eatre modifi\u00e9es. Pour obtenir les informations les plus r\u00e9centes concernant les <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/www.canadianpsoriasisnetwork.com\/provincial-territorial-programs\/\">monographies<\/a><\/u> monographies de produits, <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/?lang=eng\">faites une recherche ici<\/a><\/u>. <\/strong><\/p><h3>Programme d&#8217;aide aux patients<\/h3><p><a href=\"https:\/\/www.bioadvancemember.ca\/en\/global\/home\">https:\/\/www.bioadvancemember.ca\/en\/global\/home<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-5040 e-n-tab-title-945107942\" id=\"e-n-tab-content-945107942\" data-tab-index=\"2\" style=\"--n-tabs-title-order: 2;\" class=\" elementor-element elementor-element-9c896b2 e-con-full e-flex e-con e-child\" data-id=\"9c896b2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5040\" class=\"elementor-element elementor-element-1690efd e-flex e-con-boxed e-con e-child\" data-id=\"1690efd\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d8bca2a elementor-widget elementor-widget-shortcode\" data-id=\"d8bca2a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-shortcode\">\n<table id=\"tablepress-1-no-8\" class=\"tablepress tablepress-id-1\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Province<\/th><th class=\"column-2\">Class<\/th><th class=\"column-3\">Generic name<\/th><th class=\"column-4\">Drug Name<\/th><th class=\"column-5\">Psoriasis<\/th><th class=\"column-6\">Psoriatic arthritis<\/th><th class=\"column-7\">GPP<\/th><th class=\"column-8\">monograph<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Alberta<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">British Columbia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Manitoba<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">New Brunswick<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Newfoundland and Labrador<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">NIHB<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Northwest Territories<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Nova Scotia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Nunavut<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Ontario<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Prince Edward Island<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Quebec<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Saskatchewan<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Yukon<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Ustekinumab<\/td><td class=\"column-4\">Stelara\u00ae<\/td><td class=\"column-5\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-6\">SA - biosimilars<br \/>\nA limited number of previous Stelara (brand) patients may continue receiving coverage for this product as exceptions<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00073994.PDF<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-5041\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"2\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-5041\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Guselkumab (TREMFYA\u00ae) <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5041\" class=\"elementor-element elementor-element-4dabc9c e-con-full e-flex e-con e-child\" data-id=\"4dabc9c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5041\" class=\"elementor-element elementor-element-45d963c e-flex e-con-boxed e-con e-child\" data-id=\"45d963c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6df4a8e e-n-tabs-mobile elementor-widget elementor-widget-n-tabs\" data-id=\"6df4a8e\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;horizontal_scroll&quot;:&quot;disable&quot;}\" data-widget_type=\"nested-tabs.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-tabs\" data-widget-number=\"115296910\" aria-label=\"Onglets. Ouvrez des \u00e9l\u00e9ments avec Entrer ou Espace, fermez-les avec Echape et naviguez \u00e0 l&#039;aide des touches fl\u00e9ch\u00e9es.\">\n\t\t\t<div class=\"e-n-tabs-heading\" role=\"tablist\">\n\t\t\t\t\t<button id=\"e-n-tab-title-1152969101\" data-tab-title-id=\"e-n-tab-title-1152969101\" class=\"e-n-tab-title\" aria-selected=\"true\" data-tab-index=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"e-n-tab-content-1152969101\" style=\"--n-tabs-title-order: 1;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tD\u00e9tails\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-1152969102\" data-tab-title-id=\"e-n-tab-title-1152969102\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-1152969102\" style=\"--n-tabs-title-order: 2;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tTableaux du formulaire du programme public de m\u00e9dicaments\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t\t<\/div>\n\t\t\t<div class=\"e-n-tabs-content\">\n\t\t\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-5041 e-n-tab-title-1152969101\" id=\"e-n-tab-content-1152969101\" data-tab-index=\"1\" style=\"--n-tabs-title-order: 1;\" class=\"e-active elementor-element elementor-element-aab57eb e-con-full e-flex e-con e-child\" data-id=\"aab57eb\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5041\" class=\"elementor-element elementor-element-b6485d1 e-flex e-con-boxed e-con e-child\" data-id=\"b6485d1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8144a72 elementor-widget elementor-widget-text-editor\" data-id=\"8144a72\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Comment cela fonctionne-t-il ?<\/h3><p>Le guselkumab est un produit biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans le psoriasis. Le guselkumab agit en neutralisant l&#8217;interleukine-23. <\/p><h3>Comment est-il utilis\u00e9 ?<\/h3><p>Le guselkumab est un m\u00e9dicament injectable administr\u00e9 par voie sous-cutan\u00e9e. Le guselkumab peut \u00eatre utilis\u00e9 seul ou en association avec un antirhumatismal modificateur de la maladie conventionnel (cDMARD) tel que le m\u00e9thotrexate. <\/p><ul><li>Pour le psoriasis en plaques : 100 mg aux semaines 0 et 4, puis toutes les 8 semaines.<\/li><li>Pour le rhumatisme psoriasique : 100 mg aux semaines 0 et 4, puis toutes les 8 semaines.<\/li><\/ul><h3>Effets secondaires ?<\/h3><p>L&#8217;effet secondaire le plus fr\u00e9quent du guselkumab est un risque accru d&#8217;infections des voies respiratoires. Pour obtenir une liste compl\u00e8te de tous les effets secondaires potentiels connus du guselkumab, parlez-en \u00e0 votre m\u00e9decin ou \u00e0 votre pharmacien. <\/p><h3>Consid\u00e9rations importantes ?<\/h3><p>Certaines vaccinations, connues sous le nom de vaccinations vivantes, doivent \u00eatre \u00e9vit\u00e9es pendant le traitement par guselkumab. Avant de vous faire vacciner, demandez \u00e0 votre m\u00e9decin si le vaccin peut \u00eatre administr\u00e9 pendant le traitement par guselkumab. <\/p><p>Les patients doivent faire l&#8217;objet d&#8217;un d\u00e9pistage de la tuberculose et des infections avant le traitement.<\/p><p>N&#8217;utilisez pas <sup>TREMFYA\u00ae\/TREMFYA<\/sup> One-Press\u2122 si vous \u00eates allergique au guselkumab ou \u00e0 l&#8217;un des composants de <sup>TREMFYA\u00ae\/TREMFYA<\/sup> OnePress\u2122.<\/p><p>Si vous pensez \u00eatre allergique, demandez conseil \u00e0 votre professionnel de sant\u00e9 avant d&#8217;utiliser <sup>TREMFYA\u00ae\/TREMFYA<\/sup> One-Press\u2122.<\/p><h3>Interactions ?<\/h3><p>Pour obtenir une liste compl\u00e8te des m\u00e9dicaments susceptibles d&#8217;interagir avec le guselkumab et comprendre comment g\u00e9rer une interaction m\u00e9dicamenteuse potentielle, consultez votre m\u00e9decin ou votre pharmacien.<\/p><h3>Monographie du produit<\/h3><ul><li><a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/a><\/li><\/ul><p data-pm-slice=\"1 1 []\">La monographie est cr\u00e9\u00e9e par Sant\u00e9 Canada pour r\u00e9sumer les preuves qu&#8217;il a examin\u00e9es afin d&#8217;autoriser la vente de ce m\u00e9dicament aux patients au Canada. Elle comprend des informations sur l&#8217;indication du m\u00e9dicament (raison pour laquelle il est utilis\u00e9), ses effets secondaires et toute information relative aux avertissements de s\u00e9curit\u00e9. Ces informations sont utilis\u00e9es par les prescripteurs, les pharmaciens, les assureurs et d&#8217;autres personnes pour utiliser le m\u00e9dicament en toute s\u00e9curit\u00e9. Les informations peuvent \u00eatre tr\u00e8s d\u00e9taill\u00e9es et nous vous encourageons \u00e0 poser toutes les questions que vous souhaitez \u00e0 votre m\u00e9decin.   <\/p><p><strong>Ce site est r\u00e9guli\u00e8rement mis \u00e0 jour, mais ces informations sont susceptibles d&#8217;\u00eatre modifi\u00e9es. Pour obtenir les informations les plus r\u00e9centes concernant les <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/www.canadianpsoriasisnetwork.com\/provincial-territorial-programs\/\">monographies<\/a><\/u> monographies de produits, <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/?lang=eng\">faites une recherche ici<\/a><\/u>. <\/strong><\/p><h3>Programme d&#8217;aide aux patients<\/h3><p><a href=\"https:\/\/www.bioadvancemember.ca\/en\/global\/home\">https:\/\/www.bioadvancemember.ca\/en\/global\/home<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-5041 e-n-tab-title-1152969102\" id=\"e-n-tab-content-1152969102\" data-tab-index=\"2\" style=\"--n-tabs-title-order: 2;\" class=\" elementor-element elementor-element-9766765 e-con-full e-flex e-con e-child\" data-id=\"9766765\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5041\" class=\"elementor-element elementor-element-0e9f75f e-flex e-con-boxed e-con e-child\" data-id=\"0e9f75f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-cd460b8 elementor-widget elementor-widget-shortcode\" data-id=\"cd460b8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-shortcode\">\n<table id=\"tablepress-1-no-9\" class=\"tablepress tablepress-id-1\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Province<\/th><th class=\"column-2\">Class<\/th><th class=\"column-3\">Generic name<\/th><th class=\"column-4\">Drug Name<\/th><th class=\"column-5\">Psoriasis<\/th><th class=\"column-6\">Psoriatic arthritis<\/th><th class=\"column-7\">GPP<\/th><th class=\"column-8\">monograph<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Alberta<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">Yes \u2013 EDS<\/td><td class=\"column-6\">Yes \u2013 EDS<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">British Columbia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">Yes \u2013 EDS<\/td><td class=\"column-6\">Yes \u2013 EDS<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Manitoba<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">Yes - EDS<\/td><td class=\"column-6\">Yes - EDS<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">New Brunswick<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">Yes \u2013 S\/A<\/td><td class=\"column-6\">Yes \u2013 S\/A<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Newfoundland and Labrador<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">SA<\/td><td class=\"column-6\">SA<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">NIHB<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">Yes - L\/U<\/td><td class=\"column-6\">Yes - L\/U<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Northwest Territories<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">Yes - L\/U<\/td><td class=\"column-6\">Yes - L\/U<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Nova Scotia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">Yes \u2013 EDS<\/td><td class=\"column-6\">Yes \u2013 EDS<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Nunavut<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">Yes - L\/U<\/td><td class=\"column-6\">Yes - L\/U<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Ontario<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">Yes - L\/U<\/td><td class=\"column-6\">Yes - EAP<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Prince Edward Island<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">Yes \u2013 S\/A<\/td><td class=\"column-6\">Yes \u2013 S\/A<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Quebec<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">Yes - S\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Saskatchewan<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">Yes - EDS<\/td><td class=\"column-6\">Yes - EDS<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Yukon<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Guselkumab<\/td><td class=\"column-4\">Tremfya\u00ae<\/td><td class=\"column-5\">No<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00075605.PDF<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d27502b elementor-widget elementor-widget-heading\" data-id=\"d27502b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Abatacept<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-524e283 elementor-widget elementor-widget-n-accordion\" data-id=\"524e283\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-8630\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-8630\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Abatacept (Orencia\u00ae) <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-8630\" class=\"elementor-element elementor-element-98a06d9 e-con-full e-flex e-con e-child\" data-id=\"98a06d9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-8630\" class=\"elementor-element elementor-element-ffb2c76 e-flex e-con-boxed e-con e-child\" data-id=\"ffb2c76\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b3eb2b6 e-n-tabs-mobile elementor-widget elementor-widget-n-tabs\" data-id=\"b3eb2b6\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;horizontal_scroll&quot;:&quot;disable&quot;}\" data-widget_type=\"nested-tabs.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-tabs\" data-widget-number=\"188658358\" aria-label=\"Onglets. Ouvrez des \u00e9l\u00e9ments avec Entrer ou Espace, fermez-les avec Echape et naviguez \u00e0 l&#039;aide des touches fl\u00e9ch\u00e9es.\">\n\t\t\t<div class=\"e-n-tabs-heading\" role=\"tablist\">\n\t\t\t\t\t<button id=\"e-n-tab-title-1886583581\" data-tab-title-id=\"e-n-tab-title-1886583581\" class=\"e-n-tab-title\" aria-selected=\"true\" data-tab-index=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"e-n-tab-content-1886583581\" style=\"--n-tabs-title-order: 1;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tD\u00e9tails\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t<button id=\"e-n-tab-title-1886583582\" data-tab-title-id=\"e-n-tab-title-1886583582\" class=\"e-n-tab-title\" aria-selected=\"false\" data-tab-index=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"e-n-tab-content-1886583582\" style=\"--n-tabs-title-order: 2;\">\n\t\t\t\t\t\t<span class=\"e-n-tab-title-text\">\n\t\t\t\tTableaux du formulaire du programme public de m\u00e9dicaments\t\t\t<\/span>\n\t\t<\/button>\n\t\t\t\t\t<\/div>\n\t\t\t<div class=\"e-n-tabs-content\">\n\t\t\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-8630 e-n-tab-title-1886583581\" id=\"e-n-tab-content-1886583581\" data-tab-index=\"1\" style=\"--n-tabs-title-order: 1;\" class=\"e-active elementor-element elementor-element-436c4c1 e-con-full e-flex e-con e-child\" data-id=\"436c4c1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-8630\" class=\"elementor-element elementor-element-643f314 e-flex e-con-boxed e-con e-child\" data-id=\"643f314\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-cd5cc6d elementor-widget elementor-widget-text-editor\" data-id=\"cd5cc6d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>Comment cela fonctionne-t-il ?<\/h3><p>L&#8217;abatacept est un m\u00e9dicament biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans le <strong>rhumatisme psoriasique<\/strong>. L&#8217;abatacept agit en supprimant l&#8217;activation des globules blancs appel\u00e9s lymphocytes T. <\/p><h3>Comment est-il utilis\u00e9 ?<\/h3><p class=\"p1\">L&#8217;abatacept est un m\u00e9dicament biologique qui peut \u00eatre administr\u00e9 par voie sous-cutan\u00e9e ou intraveineuse.<\/p><h3>Effets secondaires ?<\/h3><p>Les effets secondaires les plus fr\u00e9quents de l&#8217;abatacept sont les maux de t\u00eate, les naus\u00e9es et un risque accru d&#8217;infection. Pour obtenir une liste compl\u00e8te de tous les effets secondaires potentiels connus de l&#8217;abatacept, consultez votre m\u00e9decin ou votre pharmacien. <\/p><h3>Consid\u00e9rations importantes ?<\/h3><p>Certains vaccins, connus sous le nom de vaccins vivants, doivent \u00eatre \u00e9vit\u00e9s pendant le traitement \u00e0 l&#8217;abatacept. Avant de recevoir un vaccin, demandez \u00e0 votre m\u00e9decin s&#8217;il est possible de le recevoir pendant le traitement \u00e0 l&#8217;abatacept. <\/p><p>Les patients atteints de bronchopneumopathie chronique obstructive (BPCO) pr\u00e9sentent un risque accru d&#8217;effets ind\u00e9sirables li\u00e9s \u00e0 la BPCO, tels que la toux, l&#8217;essoufflement et l&#8217;infection, lorsqu&#8217;ils sont trait\u00e9s par abatacept.<\/p><p>L&#8217;abatacept doit \u00eatre \u00e9vit\u00e9 chez les patients immunod\u00e9prim\u00e9s ou s\u00e9ropositifs.<\/p><h3>Interactions ?<\/h3><p>Parmi les m\u00e9dicaments susceptibles d&#8217;interagir avec l&#8217;abatacept figurent l&#8217;anakinra, l&#8217;adalimumab, le certolizumab pegol, l&#8217;\u00e9tanercept, le golimumab, l&#8217;infliximab, le baricitinib, le belimumab, la cladribine, l&#8217;\u00e9chinac\u00e9e, le l\u00e9flunomide, le natalizumab, le pim\u00e9crolimus, le rituximab, le roflumilast, le tacrolimus, le tocilizumab et le tofacitinib. Pour obtenir une liste compl\u00e8te des m\u00e9dicaments susceptibles d&#8217;interagir avec l&#8217;abatacept et pour comprendre comment g\u00e9rer une interaction m\u00e9dicamenteuse potentielle, consultez votre m\u00e9decin ou votre pharmacien. <\/p><h3>Monographie du produit<\/h3><ul><li><a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/a><\/li><\/ul><p data-pm-slice=\"1 1 []\">La monographie est cr\u00e9\u00e9e par Sant\u00e9 Canada pour r\u00e9sumer les preuves qu&#8217;il a examin\u00e9es afin d&#8217;autoriser la vente de ce m\u00e9dicament aux patients au Canada. Elle comprend des informations sur l&#8217;indication du m\u00e9dicament (raison pour laquelle il est utilis\u00e9), ses effets secondaires et toute information relative aux avertissements de s\u00e9curit\u00e9. Ces informations sont utilis\u00e9es par les prescripteurs, les pharmaciens, les assureurs et d&#8217;autres personnes pour utiliser le m\u00e9dicament en toute s\u00e9curit\u00e9. Les informations peuvent \u00eatre tr\u00e8s d\u00e9taill\u00e9es et nous vous encourageons \u00e0 poser toutes les questions que vous souhaitez \u00e0 votre m\u00e9decin.   <\/p><p><strong>Ce site est r\u00e9guli\u00e8rement mis \u00e0 jour, mais ces informations sont susceptibles d&#8217;\u00eatre modifi\u00e9es. Pour obtenir les informations les plus r\u00e9centes concernant les <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/www.canadianpsoriasisnetwork.com\/provincial-territorial-programs\/\">monographies<\/a><\/u> monographies de produits, <u><a class=\"ProsemirrorEditor-link\" href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/?lang=eng\">faites une recherche ici<\/a><\/u>. <\/strong><\/p><h3>Programme d&#8217;aide aux patients<\/h3><p class=\"p1\">N\/A<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div role=\"region tabpanel\" aria-labelledby=\"e-n-accordion-item-8630 e-n-tab-title-1886583582\" id=\"e-n-tab-content-1886583582\" data-tab-index=\"2\" style=\"--n-tabs-title-order: 2;\" class=\" elementor-element elementor-element-6b70c60 e-con-full e-flex e-con e-child\" data-id=\"6b70c60\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-8630\" class=\"elementor-element elementor-element-ec5cf0e e-flex e-con-boxed e-con e-child\" data-id=\"ec5cf0e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ab2c685 elementor-widget elementor-widget-shortcode\" data-id=\"ab2c685\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"shortcode.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-shortcode\">\n<table id=\"tablepress-1-no-10\" class=\"tablepress tablepress-id-1\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Province<\/th><th class=\"column-2\">Class<\/th><th class=\"column-3\">Generic name<\/th><th class=\"column-4\">Drug Name<\/th><th class=\"column-5\">Psoriasis<\/th><th class=\"column-6\">Psoriatic arthritis<\/th><th class=\"column-7\">GPP<\/th><th class=\"column-8\">monograph<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Alberta<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">British Columbia<\/td><td class=\"column-2\">Systemic Drugs<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\"><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Manitoba<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">New Brunswick<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Newfoundland and Labrador<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">NIHB<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Northwest Territories<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<tr class=\"row-9\">\n\t<td class=\"column-1\">Nova Scotia<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<tr class=\"row-10\">\n\t<td class=\"column-1\">Nunavut<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<tr class=\"row-11\">\n\t<td class=\"column-1\">Ontario<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<tr class=\"row-12\">\n\t<td class=\"column-1\">Prince Edward Island<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<tr class=\"row-13\">\n\t<td class=\"column-1\">Quebec<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<tr class=\"row-14\">\n\t<td class=\"column-1\">Saskatchewan<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<tr class=\"row-15\">\n\t<td class=\"column-1\">Yukon<\/td><td class=\"column-2\">Biologics and Biosimilars<\/td><td class=\"column-3\">Abatacept<\/td><td class=\"column-4\">Orencia\u00ae<\/td><td class=\"column-5\">N\/A<\/td><td class=\"column-6\">No<\/td><td class=\"column-7\"><\/td><td class=\"column-8\">https:\/\/pdf.hres.ca\/dpd_pm\/00070861.PDF<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Liste des produits biologiques et biosimilaires Psoriasis Bloqueurs du TNF Etanercept (Enbrel\u00ae, biosimilaires : Erelzi\u2122, Brenzys\u00ae) D\u00e9tails Tableaux du formulaire du programme public de m\u00e9dicaments Comment cela fonctionne-t-il ? L&#8217;\u00e9tanercept est un m\u00e9dicament biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans le psoriasis. L&#8217;\u00e9tanercept agit en supprimant le facteur de n\u00e9crose tumorale alpha (TNFa). Utile [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":2224,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"website_toolbox_forum_postUrl":"","website_toolbox_forum_category":"","website_toolbox_publish_on_forum":"","footnotes":""},"class_list":["post-2627","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Liste des produits biologiques et biosimilaires (rhumatisme psoriasique) - Psoriasis Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/psoriasiscanada.ca\/treatments-treating-pso-and-psa-overview\/list-of-biologics-and-biosimilars\/list-of-biologics-and-biosimilars-psoriatic-arthritis\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Liste des produits biologiques et biosimilaires (rhumatisme psoriasique) - Psoriasis Canada\" \/>\n<meta property=\"og:description\" content=\"Liste des produits biologiques et biosimilaires Psoriasis Bloqueurs du TNF Etanercept (Enbrel\u00ae, biosimilaires : Erelzi\u2122, Brenzys\u00ae) D\u00e9tails Tableaux du formulaire du programme public de m\u00e9dicaments Comment cela fonctionne-t-il ? L&#8217;\u00e9tanercept est un m\u00e9dicament biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans le psoriasis. L&#8217;\u00e9tanercept agit en supprimant le facteur de n\u00e9crose tumorale alpha (TNFa). Utile [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/psoriasiscanada.ca\/treatments-treating-pso-and-psa-overview\/list-of-biologics-and-biosimilars\/list-of-biologics-and-biosimilars-psoriatic-arthritis\/\" \/>\n<meta property=\"og:site_name\" content=\"Psoriasis Canada\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/PsoriasisCan1\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-12T22:17:20+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"109 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/psoriasiscanada.ca\\\/treatments-treating-pso-and-psa-overview\\\/list-of-biologics-and-biosimilars\\\/list-of-biologics-and-biosimilars-psoriatic-arthritis\\\/\",\"url\":\"https:\\\/\\\/psoriasiscanada.ca\\\/treatments-treating-pso-and-psa-overview\\\/list-of-biologics-and-biosimilars\\\/list-of-biologics-and-biosimilars-psoriatic-arthritis\\\/\",\"name\":\"Liste des produits biologiques et biosimilaires (rhumatisme psoriasique) - Psoriasis Canada\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/psoriasiscanada.ca\\\/#website\"},\"datePublished\":\"2026-03-10T21:53:48+00:00\",\"dateModified\":\"2026-03-12T22:17:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/psoriasiscanada.ca\\\/treatments-treating-pso-and-psa-overview\\\/list-of-biologics-and-biosimilars\\\/list-of-biologics-and-biosimilars-psoriatic-arthritis\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/psoriasiscanada.ca\\\/treatments-treating-pso-and-psa-overview\\\/list-of-biologics-and-biosimilars\\\/list-of-biologics-and-biosimilars-psoriatic-arthritis\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/psoriasiscanada.ca\\\/treatments-treating-pso-and-psa-overview\\\/list-of-biologics-and-biosimilars\\\/list-of-biologics-and-biosimilars-psoriatic-arthritis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/psoriasiscanada.ca\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Traitements &#8211; Traiter le Pso et le PsA &#8211; Vue d&#8217;ensemble\",\"item\":\"https:\\\/\\\/psoriasiscanada.ca\\\/fr\\\/traitements-traiter-le-pso-et-le-psa-vue-densemble\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Liste des produits biologiques et biosimilaires\",\"item\":\"https:\\\/\\\/psoriasiscanada.ca\\\/fr\\\/traitements-traiter-le-pso-et-le-psa-vue-densemble\\\/liste-des-produits-biologiques-et-biosimilaires\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Liste des produits biologiques et biosimilaires (rhumatisme psoriasique)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/psoriasiscanada.ca\\\/#website\",\"url\":\"https:\\\/\\\/psoriasiscanada.ca\\\/\",\"name\":\"Psoriasis Canada\",\"description\":\"Psoriasis Canada\",\"publisher\":{\"@id\":\"https:\\\/\\\/psoriasiscanada.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/psoriasiscanada.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/psoriasiscanada.ca\\\/#organization\",\"name\":\"Psoriasis Canada\",\"url\":\"https:\\\/\\\/psoriasiscanada.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/psoriasiscanada.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/psoriasiscanada.ca\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/psoriasiscanada.ca\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/logo.png\",\"width\":222,\"height\":73,\"caption\":\"Psoriasis Canada\"},\"image\":{\"@id\":\"https:\\\/\\\/psoriasiscanada.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/PsoriasisCan1\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/psoriasiscan1\",\"https:\\\/\\\/www.youtube.com\\\/@PsoriasisCan1\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Liste des produits biologiques et biosimilaires (rhumatisme psoriasique) - Psoriasis Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/psoriasiscanada.ca\/treatments-treating-pso-and-psa-overview\/list-of-biologics-and-biosimilars\/list-of-biologics-and-biosimilars-psoriatic-arthritis\/","og_locale":"fr_FR","og_type":"article","og_title":"Liste des produits biologiques et biosimilaires (rhumatisme psoriasique) - Psoriasis Canada","og_description":"Liste des produits biologiques et biosimilaires Psoriasis Bloqueurs du TNF Etanercept (Enbrel\u00ae, biosimilaires : Erelzi\u2122, Brenzys\u00ae) D\u00e9tails Tableaux du formulaire du programme public de m\u00e9dicaments Comment cela fonctionne-t-il ? L&#8217;\u00e9tanercept est un m\u00e9dicament biologique qui cible l&#8217;hyperactivit\u00e9 du syst\u00e8me immunitaire dans le psoriasis. L&#8217;\u00e9tanercept agit en supprimant le facteur de n\u00e9crose tumorale alpha (TNFa). Utile [&hellip;]","og_url":"https:\/\/psoriasiscanada.ca\/treatments-treating-pso-and-psa-overview\/list-of-biologics-and-biosimilars\/list-of-biologics-and-biosimilars-psoriatic-arthritis\/","og_site_name":"Psoriasis Canada","article_publisher":"https:\/\/www.facebook.com\/PsoriasisCan1","article_modified_time":"2026-03-12T22:17:20+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"109 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/psoriasiscanada.ca\/treatments-treating-pso-and-psa-overview\/list-of-biologics-and-biosimilars\/list-of-biologics-and-biosimilars-psoriatic-arthritis\/","url":"https:\/\/psoriasiscanada.ca\/treatments-treating-pso-and-psa-overview\/list-of-biologics-and-biosimilars\/list-of-biologics-and-biosimilars-psoriatic-arthritis\/","name":"Liste des produits biologiques et biosimilaires (rhumatisme psoriasique) - Psoriasis Canada","isPartOf":{"@id":"https:\/\/psoriasiscanada.ca\/#website"},"datePublished":"2026-03-10T21:53:48+00:00","dateModified":"2026-03-12T22:17:20+00:00","breadcrumb":{"@id":"https:\/\/psoriasiscanada.ca\/treatments-treating-pso-and-psa-overview\/list-of-biologics-and-biosimilars\/list-of-biologics-and-biosimilars-psoriatic-arthritis\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/psoriasiscanada.ca\/treatments-treating-pso-and-psa-overview\/list-of-biologics-and-biosimilars\/list-of-biologics-and-biosimilars-psoriatic-arthritis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/psoriasiscanada.ca\/treatments-treating-pso-and-psa-overview\/list-of-biologics-and-biosimilars\/list-of-biologics-and-biosimilars-psoriatic-arthritis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/psoriasiscanada.ca\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Traitements &#8211; Traiter le Pso et le PsA &#8211; Vue d&#8217;ensemble","item":"https:\/\/psoriasiscanada.ca\/fr\/traitements-traiter-le-pso-et-le-psa-vue-densemble\/"},{"@type":"ListItem","position":3,"name":"Liste des produits biologiques et biosimilaires","item":"https:\/\/psoriasiscanada.ca\/fr\/traitements-traiter-le-pso-et-le-psa-vue-densemble\/liste-des-produits-biologiques-et-biosimilaires\/"},{"@type":"ListItem","position":4,"name":"Liste des produits biologiques et biosimilaires (rhumatisme psoriasique)"}]},{"@type":"WebSite","@id":"https:\/\/psoriasiscanada.ca\/#website","url":"https:\/\/psoriasiscanada.ca\/","name":"Psoriasis Canada","description":"Psoriasis Canada","publisher":{"@id":"https:\/\/psoriasiscanada.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/psoriasiscanada.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/psoriasiscanada.ca\/#organization","name":"Psoriasis Canada","url":"https:\/\/psoriasiscanada.ca\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/psoriasiscanada.ca\/#\/schema\/logo\/image\/","url":"https:\/\/psoriasiscanada.ca\/wp-content\/uploads\/2025\/11\/logo.png","contentUrl":"https:\/\/psoriasiscanada.ca\/wp-content\/uploads\/2025\/11\/logo.png","width":222,"height":73,"caption":"Psoriasis Canada"},"image":{"@id":"https:\/\/psoriasiscanada.ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/PsoriasisCan1","https:\/\/www.linkedin.com\/in\/psoriasiscan1","https:\/\/www.youtube.com\/@PsoriasisCan1"]}]}},"_links":{"self":[{"href":"https:\/\/psoriasiscanada.ca\/fr\/wp-json\/wp\/v2\/pages\/2627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/psoriasiscanada.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/psoriasiscanada.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/psoriasiscanada.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/psoriasiscanada.ca\/fr\/wp-json\/wp\/v2\/comments?post=2627"}],"version-history":[{"count":4,"href":"https:\/\/psoriasiscanada.ca\/fr\/wp-json\/wp\/v2\/pages\/2627\/revisions"}],"predecessor-version":[{"id":2646,"href":"https:\/\/psoriasiscanada.ca\/fr\/wp-json\/wp\/v2\/pages\/2627\/revisions\/2646"}],"up":[{"embeddable":true,"href":"https:\/\/psoriasiscanada.ca\/fr\/wp-json\/wp\/v2\/pages\/2224"}],"wp:attachment":[{"href":"https:\/\/psoriasiscanada.ca\/fr\/wp-json\/wp\/v2\/media?parent=2627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}